{"content":"<li class=\"n-box-item date-title\" data-end=\"1545109199\" data-start=\"1545022800\" data-txt=\"Monday, December 23, 2019\">Monday, December 17, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3417735\" data-ts=\"1545091719\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRIN\" target=\"_blank\">MRIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417735-marin-softwareplus-50-on-google-revenue-sharing-deal-updated-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marin Software +50% on Google revenue sharing deal, updated guidance</a></h4><ul><li>Marin Software (NASDAQ:<a href='https://seekingalpha.com/symbol/MRIN' title='Marin Software'>MRIN</a>) <font color=\"green\">+50.7%</font> after-hours on news it entered into a three-year <a href=\"https://seekingalpha.com/pr/17360554-marin-software-announces-updated-fourth-quarter-2018-guidance\" target=\"_blank\">revenue sharing agreement with Google</a> to further develop the company's enterprise tech platform and software products.</li><li>MRIN will receive revenue payments from Google based on \"revenue generated on the company's tech platform in connection with the company's clients' spend on search ads... appearing on Google Search only, during a relevant calendar quarter\" and \"in connection with its clients' spend on search ads appearing on the eligible search engines... excluding Google Search, during the relevant contract year,\" according to an <a href=\"https://www.sec.gov/Archives/edgar/data/1389002/000143774918022123/mrin20181217_8k.htm\" target=\"_blank\">SEC filing</a>.</li><li>As a result of the Google deal, MRIN <a href=\"https://www.marketwatch.com/story/marin-softwares-stock-rockets-60-on-google-revenue-pact-2018-12-17\" target=\"_blank\">updates Q4 guidance</a>, now expecting revenue of $14.6M-$15.1M after earlier forecasting $11.6M-$12.1M and anticipates an adjusted operating loss of $2.4M-$2.9M instead of its previous outlook for a loss of $5.4M-$5.9M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417735\" data-linked=\"Marin Software +50% on Google revenue sharing deal, updated guidance\" data-tweet=\"$MRIN - Marin Software +50% on Google revenue sharing deal, updated guidance https://seekingalpha.com/news/3417735-marin-softwareplus-50-on-google-revenue-sharing-deal-updated-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3417735-marin-softwareplus-50-on-google-revenue-sharing-deal-updated-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417727\" data-ts=\"1545086512\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBYI\" target=\"_blank\">PBYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417727-after-hours-gainers-losers-12-17-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (12/17/2018)</a></h4><ul><li><b>Top Gainers:</b> <a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color=\"green\">+9.2%</font>. <a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a> <font color=\"green\">+7.2%</font>. <a href='https://seekingalpha.com/symbol/BRY' title='Berry Petroleum Corp.'>BRY</a> <font color=\"green\">+3.6%</font>.</li><li><b>Top Losers:</b> <a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a> <font color=\"red\">-4.1%</font>. <a href='https://seekingalpha.com/symbol/CTT' title='CatchMark Timber Trust, Inc.'>CTT</a> <font color=\"red\">-2.3%</font>. <a href='https://seekingalpha.com/symbol/TVIX' title='VelocityShares Daily 2x VIX Short-Term ETN'>TVIX</a> <font color=\"red\">-1.9%.</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3417727\" data-linked=\"After Hours Gainers / Losers (12/17/2018)\" data-tweet=\"$PBYI $PBYI $SND - After Hours Gainers / Losers (12/17/2018) https://seekingalpha.com/news/3417727-after-hours-gainers-losers-12-17-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3417727-after-hours-gainers-losers-12-17-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417722\" data-ts=\"1545085058\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EHTH\" target=\"_blank\">EHTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417722-ehealth-files-for-150m-mixed-shelf-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EHealth files for $150M mixed shelf offering</a></h4><ul><li>EHealth (NASDAQ:<a href='https://seekingalpha.com/symbol/EHTH' title='eHealth, Inc.'>EHTH</a>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1333493/000162828018015185/s-3.htm\" target=\"_blank\">prospectus</a> for a $150M mixed shelf offering.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417722\" data-linked=\"EHealth files for $150M mixed shelf offering\" data-tweet=\"$EHTH - EHealth files for $150M mixed shelf offering https://seekingalpha.com/news/3417722-ehealth-files-for-150m-mixed-shelf-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3417722-ehealth-files-for-150m-mixed-shelf-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417721\" data-ts=\"1545084911\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLPG\" target=\"_blank\">GLPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417721-galapagos-commences-late-stage-studies-of-glpg1690-in-ipf-shares-up-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galapagos commences late-stage studies of GLPG1690 in IPF; shares up 1% after hours</a></h4><ul><li>Galapagos NV (NASDAQ:<a href='https://seekingalpha.com/symbol/GLPG' title='Galapagos'>GLPG</a>) is up <font color=\"green\">1%</font> after hours on the heels of its <a href=\"https://seekingalpha.com/pr/17360484-galapagos-reports-initiation-isabela-phase-3-program-glpg1690-patients-idiopathic-pulmonary\" target=\"_blank\">announcement </a>that dosing is underway in its Phase 3 program for autotaxin inhibitor GLPG1690 in patients with idiopathic pulmonary fibrosis &#40;IPF&#41;.</li><li>The program consists of two Phase 3s: <a href=\"https://clinicaltrials.gov/ct2/show/NCT03711162?intr=GLPG1690&amp;lead=galapagos&amp;phase=2&amp;rank=2\" target=\"_blank\">ISABELA1</a> and <a href=\"https://clinicaltrials.gov/ct2/show/NCT03733444?intr=GLPG1690&amp;lead=galapagos&amp;phase=2&amp;rank=1\" target=\"_blank\">ISABELA2</a>, assessing GLPG1690 plus standard-of-care treatment. Both should wind up in late 2021.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417721\" data-linked=\"Galapagos commences late-stage studies of GLPG1690 in IPF; shares up 1% after hours\" data-tweet=\"$GLPG - Galapagos commences late-stage studies of GLPG1690 in IPF; shares up 1% after hours https://seekingalpha.com/news/3417721-galapagos-commences-late-stage-studies-of-glpg1690-in-ipf-shares-up-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3417721-galapagos-commences-late-stage-studies-of-glpg1690-in-ipf-shares-up-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417718\" data-ts=\"1545084511\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOTS\" target=\"_blank\">MOTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417718-motus-gi-launches-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Motus GI launches stock offering</a></h4><ul><li>Motus GI Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MOTS' title='Motus GI Holdings'>MOTS</a>) <a href=\"https://seekingalpha.com/pr/17360480-motus-gi-announces-launch-proposed-follow-public-offering\" target=\"_blank\">initiates </a>a public offering of 5M shares of common stock. Price and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417718\" data-linked=\"Motus GI launches stock offering\" data-tweet=\"$MOTS - Motus GI launches stock offering https://seekingalpha.com/news/3417718-motus-gi-launches-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3417718-motus-gi-launches-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417715\" data-ts=\"1545084416\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLXT\" target=\"_blank\">CLXT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417715-calyxt-nabs-european-patent-for-method-of-gene-editing-plants-shares-up-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Calyxt nabs European patent for method of gene editing plants; shares up 1% after hours</a></h4><ul><li>Calyxt (NASDAQ:<a href='https://seekingalpha.com/symbol/CLXT' title='Calyxt, Inc.'>CLXT</a>) is up <font color=\"green\">1%</font> after hours in reaction to its <a href=\"https://seekingalpha.com/pr/17360506-calyxt-receives-eu-patent-use-crispr-cas9-genome-editing-plants\" target=\"_blank\">announcement </a>that the European Patent Office has issued it a new patent covering methods to create gene-edited plants by transient delivery of sequence-specific nucleases, including CRISPR/Cas9.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417715\" data-linked=\"Calyxt nabs European patent for method of gene editing plants; shares up 1% after hours\" data-tweet=\"$CLXT - Calyxt nabs European patent for method of gene editing plants; shares up 1% after hours https://seekingalpha.com/news/3417715-calyxt-nabs-european-patent-for-method-of-gene-editing-plants-shares-up-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3417715-calyxt-nabs-european-patent-for-method-of-gene-editing-plants-shares-up-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417704\" data-ts=\"1545083639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBYI\" target=\"_blank\">PBYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417704-puma-bios-neratinib-shows-positive-action-in-late-stage-breast-cancer-study-shares-up-9-after\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Puma Bio&#39;s neratinib shows positive action in late-stage breast cancer study; shares up 9% after hours</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17360444-puma-biotechnology-announces-top-line-results-phase-iii-nala-trial-neratinib-patients-her2\" target=\"_blank\">Results</a> from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT01808573?titles=nala&amp;lead=puma&amp;rank=1\" target=\"_blank\">NALA</a>, evaluating Puma Biotechnology's (NYSE:<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a>) lead drug PB272 (neratinib) in treatment-resistant HER2-positive breast cancer patients showed a positive effect.</li><li>The study assessed neratinib plus capecitabine [Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>) Xeloda] compared to Novartis' (NYSE:<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>) Tykerb (lapatinib) plus capecitabine in a third-line setting. Patients in the neratinib arm experienced a statistically significant improvement in centrally confirmed progression-free survival &#40;PFS&#41; versus lapatinib + capecitabine. Overall survival favored neratinib but the separation fell short of statistical significance.</li><li>Complete results will be submitted to global health authorities and for presentation at a future medical conference.</li><li>Shares are up <font color=\"green\">9%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417704\" data-linked=\"Puma Bio&#39;s neratinib shows positive action in late-stage breast cancer study; shares up 9% after hours\" data-tweet=\"$PBYI $PBYI $RHHBY - Puma Bio&#39;s neratinib shows positive action in late-stage breast cancer study; shares up 9% after hours https://seekingalpha.com/news/3417704-puma-bios-neratinib-shows-positive-action-in-late-stage-breast-cancer-study-shares-up-9-after?source=tweet\" data-url=\"https://seekingalpha.com/news/3417704-puma-bios-neratinib-shows-positive-action-in-late-stage-breast-cancer-study-shares-up-9-after\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417687\" data-ts=\"1545082645\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBY\" target=\"_blank\">BBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417687-negative-read-on-consumer-electronics-toys-spending\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Negative read on consumer electronics/toys spending</a></h4><ul> <li>Bank of America Merrill Lynch credit card data shows a 6% drop in spending on consumer electronics and toys for November. The sharp drop during the month is the biggest recorded over the last few years.</li> <li>The BAML chart on consumer electronics/toys sales was buried in a downgrade note posted by the firm earlier today on Best Buy (NYSE:<a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a>), but certainly seems relevant to Mattel (NASDAQ:<a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a>) and Hasbro (NASDAQ:<a href='https://seekingalpha.com/symbol/HAS' title='Hasbro, Inc.'>HAS</a>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3417687\" data-linked=\"Negative read on consumer electronics/toys spending\" data-tweet=\"$BBY $BBY $MAT - Negative read on consumer electronics/toys spending https://seekingalpha.com/news/3417687-negative-read-on-consumer-electronics-toys-spending?source=tweet\" data-url=\"https://seekingalpha.com/news/3417687-negative-read-on-consumer-electronics-toys-spending\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417667\" data-ts=\"1545081610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORCL\" target=\"_blank\">ORCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417667-oracleplus-3_5-on-q2-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oracle +3.5% on Q2 beats</a></h4><ul><li>Oracle (NYSE:<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a>) <font color=\"green\">gains 3.5% </font>after reporting Q2 beats and in-line and better segment results. Guidance will come on the earnings call.</li><li>Revenue breakdown: Cloud Services and License Support, $6.64B (consensus: $6.63B); Cloud License and On-Premise License, $1.22B (consensus: $1.18B); Hardware, $891M ($891.9M); Services, $817M ($817.7M).</li><li>Earnings call is scheduled for 5 PM ET with a webcast available <a href=\"https://investor.oracle.com/overview/highlights/default.aspx\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17360440-q2-fy19-gaap-eps-18-percent-0_61-non-gaap-eps-16-percent-0_80\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417649-oracle-beats-0_02-beats-revenue\" target=\"_blank\">Oracle beats by $0.02, beats on revenue</a> (Dec. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3417667\" data-linked=\"Oracle +3.5% on Q2 beats\" data-tweet=\"$ORCL - Oracle +3.5% on Q2 beats https://seekingalpha.com/news/3417667-oracleplus-3_5-on-q2-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3417667-oracleplus-3_5-on-q2-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417666\" data-ts=\"1545081581\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACHN\" target=\"_blank\">ACHN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417666-achillion-up-2-after-hours-on-positive-achminus-4471-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Achillion up 2% after hours on positive ACH-4471 data</a></h4><ul><li>Achillion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a>) is up <font color=\"green\">2%</font> after hours in response to its <a href=\"https://seekingalpha.com/pr/17360438-achillion-reports-positive-interim-data-achminus-4471-phase-2-trials-provides-clinical\" target=\"_blank\">announcement </a>of interim data from its Phase 2 studies of complement factor D inhibitor ACH-4471, alone and with a C5 inhibitor, in patients with paroxysmal nocturnal hemoglobinuria &#40;PNH&#41; and C3 glomerulopathy (C3G). The company says it has demonstrated proof of concept in both indications. It plans to review the results with the FDA in Q4 2019.</li><li>Its next-generation factor D inhibitors, ACH-5228 and ACH-5548, are in Phase 1 development.</li><li>Management will host a conference call at 4:30 pm ET to discuss the data.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417666\" data-linked=\"Achillion up 2% after hours on positive ACH-4471 data\" data-tweet=\"$ACHN - Achillion up 2% after hours on positive ACH-4471 data https://seekingalpha.com/news/3417666-achillion-up-2-after-hours-on-positive-achminus-4471-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3417666-achillion-up-2-after-hours-on-positive-achminus-4471-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417655\" data-ts=\"1545080856\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417655-averages-give-back-another-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Averages give back another 2%</a></h4><ul><li>A bit of buying into the close took the averages off of their worst levels, but the Dow and S&amp;P 500 still <font color=\"red\">shed 2.1%</font> and the Nasdaq <font color=\"red\">2.3%</font>.</li><li>The S&amp;P 500 is now at a new low for the year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417655\" data-linked=\"Averages give back another 2%\" data-tweet=\"Averages give back another 2% https://seekingalpha.com/news/3417655-averages-give-back-another-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3417655-averages-give-back-another-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417646\" data-ts=\"1545080206\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAT\" target=\"_blank\">MAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417646-mattel-slumps-to-52-week-low\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mattel slumps to 52-week low</a></h4><ul> <li>Mattel (NASDAQ:<a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a>) is <font color=\"red\">down 5.55%</font> amid more concerns on the  impact of China tariffs to the company's bottom line.</li> <li>Shares carved out a new 52-week low of $10.86 earlier in the session.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3417646\" data-linked=\"Mattel slumps to 52-week low\" data-tweet=\"$MAT - Mattel slumps to 52-week low https://seekingalpha.com/news/3417646-mattel-slumps-to-52-week-low?source=tweet\" data-url=\"https://seekingalpha.com/news/3417646-mattel-slumps-to-52-week-low\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417645\" data-ts=\"1545080126\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSAT\" target=\"_blank\">GSAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417645-globalstarplus-26-on-litigation-settlement-3gpp-approval\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Globalstar +26% on litigation settlement, 3GPP approval</a></h4><ul><li>Globalstar (<a href='https://seekingalpha.com/symbol/GSAT' title='Globalstar, Inc.'>GSAT</a> <font color='green'>+26.6%</font>) surges on news it <a href=\"https://seekingalpha.com/pr/17359594-globalstar-mudrick-capital-management-warlander-asset-management-announce-settlement\" target=\"_blank\">settled a lawsuit</a> with minority shareholders, agreeing to sweeping changes in its corporate governance designed partly to prevent transactions by Executive Chairman Jay Monroe.</li><li>GSAT will add three new \"seasoned telecom executives\" to its board to fill three vacancies left by existing board members.</li><li>Also, GSAT said the Third Generation Partnership Project <a href=\"https://seekingalpha.com/pr/17359843-globalstar-announces-3gpp-approval-band-53-2_4-ghz-terrestrial-spectrum\" target=\"_blank\">approved a global standard</a> for use of some spectrum that the company owns but has struggled to monetize.</li><li>3GPP designates GSAT\u2019s terrestrial S-band as Band 53, which now permits LTE services in the U.S. with additional geographies expected to be added in 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417645\" data-linked=\"Globalstar +26% on litigation settlement, 3GPP approval\" data-tweet=\"$GSAT - Globalstar +26% on litigation settlement, 3GPP approval https://seekingalpha.com/news/3417645-globalstarplus-26-on-litigation-settlement-3gpp-approval?source=tweet\" data-url=\"https://seekingalpha.com/news/3417645-globalstarplus-26-on-litigation-settlement-3gpp-approval\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417636\" data-ts=\"1545079540\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLY\" target=\"_blank\">NLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417636-mortgage-reits-taking-no-heart-from-declining-rates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mortgage REITs taking no heart from declining rates</a></h4><ul><li>The mortgage REIT sector might seem to welcome what could be at least the temporary end of the Fed's rate hike cycle. Not today, though. With the S&amp;P 500 <font color=\"red\">down 2.4%</font>, the 10-year Treasury yield at a new multi-month low, and traders bailing on rate hike expectations for next year (not to mention this week), the iShares Mortgage Real Estate Capped ETF (BATS:<a href='https://seekingalpha.com/symbol/REM' title='iShares Mortgage Real Estate Capped ETF'>REM</a>) is <font color=\"red\">down 3.25%</font>.</li><li>Individual players: Annaly Capital (<a href='https://seekingalpha.com/symbol/NLY' title='Annaly Capital Management, Inc.'>NLY</a> <font color=\"red\">-2.5%</font>), AGNC Investment (<a href='https://seekingalpha.com/symbol/AGNC' title='AGNC Investment Corp.'>AGNC</a> <font color=\"red\">-2%</font>), Two Harbors (<a href='https://seekingalpha.com/symbol/TWO' title='Two Harbors Investment Corp.'>TWO</a> <font color=\"red\">-2.6%</font>), Armour (<a href='https://seekingalpha.com/symbol/ARR' title='ARMOUR Residential REIT, Inc.'>ARR</a> <font color=\"red\">-3.7%</font>), Orchid Island (<a href='https://seekingalpha.com/symbol/ORC' title='Orchid Island Capital'>ORC</a> <font color=\"red\">-8.2%</font>), Western Asset (<a href='https://seekingalpha.com/symbol/WMC' title='Western Asset Mortgage Capital Corporation'>WMC</a> <font color=\"red\">-6.6%</font>), Invesco (<a href='https://seekingalpha.com/symbol/IVR' title='Invesco Mortgage Capital Inc.'>IVR</a> <font color=\"red\">-3.4%</font>), Dynex (<a href='https://seekingalpha.com/symbol/DX' title='Dynex Capital Inc.'>DX</a> <font color=\"red\">-3.7%</font>), Capstead (<a href='https://seekingalpha.com/symbol/CMO' title='Capstead Mortgage Corporation'>CMO</a> <font color=\"red\">-4.9%</font>), PennyMac (<a href='https://seekingalpha.com/symbol/PMT' title='PennyMac Mortgage Investment Trust'>PMT</a> <font color=\"red\">-5.5%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/MORL' title='UBS ETRACS Monthly Pay 2x Leveraged Mortgage REIT ETN'>MORL</a>, <a href='https://seekingalpha.com/symbol/REM' title='iShares Mortgage Real Estate Capped ETF'>REM</a>, <a href='https://seekingalpha.com/symbol/MORT' title='VanEck Vectors Mortgage REIT Income ETF'>MORT</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3417636\" data-linked=\"Mortgage REITs taking no heart from declining rates\" data-tweet=\"$NLY $REM $NLY - Mortgage REITs taking no heart from declining rates https://seekingalpha.com/news/3417636-mortgage-reits-taking-no-heart-from-declining-rates?source=tweet\" data-url=\"https://seekingalpha.com/news/3417636-mortgage-reits-taking-no-heart-from-declining-rates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>58&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417635\" data-ts=\"1545079315\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSEC\" target=\"_blank\">PSEC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417635-bdcs-punished-in-selloff\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BDCs punished in selloff</a></h4><ul><li>BDCs might be income favorites, but they're also proxies for general corporate credit, which is under pressure. And that might be particularly so in the oil patch, with crude once again plunging below $50 per barrel.</li><li>Among today's movers: Prospect Capital (<a href='https://seekingalpha.com/symbol/PSEC' title='Prospect Capital Corporation'>PSEC</a> <font color='red'>-4.9%</font>), Main Street Capital (<a href='https://seekingalpha.com/symbol/MAIN' title='Main Street Capital'>MAIN</a> <font color='red'>-4.9%</font>), Ares Capital (<a href='https://seekingalpha.com/symbol/ARCC' title='Ares Capital'>ARCC</a> <font color='red'>-5.2%</font>), Apollo Investment (<a href='https://seekingalpha.com/symbol/AINV' title='Apollo Investment'>AINV</a> <font color='red'>-4.7%</font>), Gladstone Investment (<a href='https://seekingalpha.com/symbol/GAIN' title='Gladstone Investment'>GAIN</a> <font color='red'>-4.9%</font>), Newtek Business (<a href='https://seekingalpha.com/symbol/NEWT' title='Newtek Business Services Inc.'>NEWT</a> <font color='red'>-8.1%</font>), PennantPark (<a href='https://seekingalpha.com/symbol/PNNT' title='PennantPark Investment'>PNNT</a> <font color='red'>-6.6%</font>), Blackrock TCP (<a href='https://seekingalpha.com/symbol/TCPC' title='TCP Capital'>TCPC</a> <font color='red'>-4.9%</font>), Goldman Sachs BDC (<a href='https://seekingalpha.com/symbol/GSBD' title='Goldman Sachs BDC'>GSBD</a> <font color='red'>-5.1%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/BDCL' title='UBS ETRACS 2X Leveraged Long Wells Fargo Business Development Company ETN'>BDCL</a>, <a href='https://seekingalpha.com/symbol/BDCS' title='UBS ETRACS Wells Fargo Business Development Company ETN'>BDCS</a>, <a href='https://seekingalpha.com/symbol/BIZD' title='VanEck Vectors BDC Income ETF'>BIZD</a>, <a href='https://seekingalpha.com/symbol/FGB' title='First Trust Specialty Finance&Financial Opportunities Fund'>FGB</a>, <a href='https://seekingalpha.com/symbol/LBDC' title='ETRACS 2x Leveraged Long Wells Fargo Business Development Company Index ETN Series B'>LBDC</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3417635\" data-linked=\"BDCs punished in selloff\" data-tweet=\"$PSEC $PSEC $MAIN - BDCs punished in selloff https://seekingalpha.com/news/3417635-bdcs-punished-in-selloff?source=tweet\" data-url=\"https://seekingalpha.com/news/3417635-bdcs-punished-in-selloff\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>189&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417629\" data-ts=\"1545078634\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417629-utilities-reits-slammed-along-rest-of-market\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Utilities, REITs slammed along with rest of market</a></h4><ul><li>Not even defensive plays are working today, with utilities (<a href='https://seekingalpha.com/symbol/XLU' title='Utilities Select Sector SPDR ETF'>XLU</a> <font color='red'>-3.2%</font>) and REITs (<a href='https://seekingalpha.com/symbol/IYR' title='iShares U.S. Real Estate ETF'>IYR</a> <font color='red'>-2.9%</font>) down even more than the broader averages.</li><li>The 10-year Treasury yield, meanwhile, is down four basis points to a multi-month low of 2.855%, and traders continue to see about a 50% chance of a Fed rate hike this week (we'd put the odds at closer to zero). <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a> <font color=\"green\">+0.55%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a> <font color=\"red\">-1.1%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/VNQ' title='Vanguard Real Estate ETF'>VNQ</a>, <a href='https://seekingalpha.com/symbol/IYR' title='iShares U.S. Real Estate ETF'>IYR</a>, <a href='https://seekingalpha.com/symbol/XLU' title='Utilities Select Sector SPDR ETF'>XLU</a>, <a href='https://seekingalpha.com/symbol/UTG' title='Reaves Utility Income Fund'>UTG</a>, <a href='https://seekingalpha.com/symbol/RQI' title='Cohen&Steers Quality Income Realty Fund'>RQI</a>, <a href='https://seekingalpha.com/symbol/VPU' title='Vanguard Utilities ETF'>VPU</a>, <a href='https://seekingalpha.com/symbol/SCHH' title='Schwab U.S. REIT ETF'>SCHH</a>, <a href='https://seekingalpha.com/symbol/RNP' title='Cohen&Steers REIT&Preferred Income Fund'>RNP</a>, <a href='https://seekingalpha.com/symbol/RFI' title='Cohen&Steers Total Return Realty Fund'>RFI</a>, <a href='https://seekingalpha.com/symbol/GUT' title='Gabelli Utility Trust'>GUT</a>, <a href='https://seekingalpha.com/symbol/IDU' title='iShares U.S. Utilities ETF'>IDU</a>, <a href='https://seekingalpha.com/symbol/KBWY' title='Invesco KBW Premium Yield Equity REIT Portfolio ETF'>KBWY</a>, <a href='https://seekingalpha.com/symbol/DRN' title='Direxion Daily Real Estate Bull 3x Shares ETF'>DRN</a>, <a href='https://seekingalpha.com/symbol/BUI' title='BlackRock Utility&Infrastructure Trust'>BUI</a>, <a href='https://seekingalpha.com/symbol/NRO' title='Neuberger Berman Real Estate Securities Income Fund'>NRO</a>, <a href='https://seekingalpha.com/symbol/URE' title='ProShares Ultra Real Estate ETF'>URE</a>, <a href='https://seekingalpha.com/symbol/ICF' title='iShares Cohen & Steers REIT ETF'>ICF</a>, <a href='https://seekingalpha.com/symbol/XLRE' title='Real Estate Select Sector SPDR ETF'>XLRE</a>, <a href='https://seekingalpha.com/symbol/JRS' title='Nuveen Real Estate Income Fund'>JRS</a>, <a href='https://seekingalpha.com/symbol/RWR' title='SPDR Dow Jones REIT ETF'>RWR</a>, <a href='https://seekingalpha.com/symbol/SRS' title='ProShares UltraShort Real Estate ETF'>SRS</a>, <a href='https://seekingalpha.com/symbol/FUTY' title='Fidelity MSCI Utilities Index ETF'>FUTY</a>, <a href='https://seekingalpha.com/symbol/FREL' title='Fidelity MSCI Real Estate Index ETF'>FREL</a>, <a href='https://seekingalpha.com/symbol/DRA' title='Diversified Real Asset Income Fund'>DRA</a>, <a href='https://seekingalpha.com/symbol/DRV' title='Direxion Daily Real Estate Bear 3x Shares ETF'>DRV</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3417629\" data-linked=\"Utilities, REITs slammed along with rest of market\" data-tweet=\"$XLU $IYR $TLT - Utilities, REITs slammed along with rest of market https://seekingalpha.com/news/3417629-utilities-reits-slammed-along-rest-of-market?source=tweet\" data-url=\"https://seekingalpha.com/news/3417629-utilities-reits-slammed-along-rest-of-market\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>102&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417628\" data-ts=\"1545078333\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UEEC\" target=\"_blank\">UEEC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417628-united-health-products-to-host-business-update-december-20-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United Health Products to host business update December 20; shares up 2%</a></h4><ul><li>United Health Products (<a href='https://seekingalpha.com/symbol/UEEC' title='United Health Products, Inc.'>OTCPK:UEEC</a> <font color=\"green\">+1.7%</font>) will host a <a href=\"https://seekingalpha.com/pr/17360299-united-health-products-hold-conference-call-december-20-2018-discuss-recent-corporate\" target=\"_blank\">conference call</a> on Thursday, December 20, at 11:30 am ET to update investors on its business.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417628\" data-linked=\"United Health Products to host business update December 20; shares up 2%\" data-tweet=\"$UEEC - United Health Products to host business update December 20; shares up 2% https://seekingalpha.com/news/3417628-united-health-products-to-host-business-update-december-20-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3417628-united-health-products-to-host-business-update-december-20-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417627\" data-ts=\"1545077669\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BASFY\" target=\"_blank\">BASFY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417627-basf-to-keep-raising-prices-to-offset-higher-raw-material-costs-cfo-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BASF to keep raising prices to offset higher raw material costs, CFO says</a></h4><ul><li>BASF (<a href='https://seekingalpha.com/symbol/BASFY' title='BASF SE ADR'>OTCQX:BASFY</a> <font color='red'>-1.4%</font>) is <a href=\"https://www.wsj.com/articles/germanys-basf-plans-more-price-increases-to-offset-higher-raw-material-costs-11545073175\" target=\"_blank\">planning more price increases in 2019</a> to offset the impact of higher raw materials costs, CFO Hans-Ulrich Engel says in a <em>WSJ</em> interview.</li><li>BASF has raised prices by 5%-6% across its product range since the beginning of 2018 but the CFO says this has not been sufficient to offset the temporary run-up in oil and gas prices that is affecting the company's downstream business.</li><li>Brent crude oil prices topped $85/bbl earlier in the fall, and BASF this year paid \u20ac4-\u20ac5 more for each kilowatt-hour of gas compared with last year, according to Engel, who says the company is \"countering with price hikes... but it takes a while to push them through,\" adding that the recent oil price decline complicates the task.</li><li>Analysts say BASF was late to raise prices in response to higher input costs, and now that raw material costs are again pulling lower, the company is struggling to explain the continued price increases to its customers.</li><li>The U.K.\u2019s exit from the European Union could present more challenges for the company, Engel says: BASF is concerned by the prospect of a no-deal Brexit, as the EU\u2019s regulatory framework for chemicals might no longer apply to the U.K. and could lead to a regulatory vacuum that could force the company to stop supplying its customers.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417627\" data-linked=\"BASF to keep raising prices to offset higher raw material costs, CFO says\" data-tweet=\"$BASFY - BASF to keep raising prices to offset higher raw material costs, CFO says https://seekingalpha.com/news/3417627-basf-to-keep-raising-prices-to-offset-higher-raw-material-costs-cfo-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3417627-basf-to-keep-raising-prices-to-offset-higher-raw-material-costs-cfo-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417626\" data-ts=\"1545077478\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TMUS\" target=\"_blank\">TMUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417626-wsj-cfius-clears-t-mobile-sprint-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ: CFIUS clears T-Mobile, Sprint merger</a></h4><ul><li><a href=\"https://www.wsj.com/articles/t-mobile-takeover-of-sprint-clears-u-s-national-security-panel-11545076651\" target=\"_blank\"><em>WSJ</em> sources</a> say the Committee on Foreign Investment in the U.S. has approved the T-Mobile (<a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a> <font color=\"red\">-1.3%</font>) and Sprint (<a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a> <font color=\"red\">-1.8%</font>) merger, clearing the deal of potential national security issues.</li><li>The deal still needs approval from the FCC and Justice Department. T-Mobile execs expect those decisions in 2H19.</li><li>Post updated to correct FTC to FCC.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417626\" data-linked=\"WSJ: CFIUS clears T-Mobile, Sprint merger\" data-tweet=\"$TMUS $TMUS $S - WSJ: CFIUS clears T-Mobile, Sprint merger https://seekingalpha.com/news/3417626-wsj-cfius-clears-t-mobile-sprint-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3417626-wsj-cfius-clears-t-mobile-sprint-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417623\" data-ts=\"1545077006\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ETSY\" target=\"_blank\">ETSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417623-aegis-names-internet-m-potentials-for-2019\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aegis names internet M&amp;A potentials for 2019</a></h4><ul><li>Aegis Capital analyst Victor Anthony thinks several SMID cap Internet names might be acquisition targets if the economy slows next year.</li><li>Anthony lists the potential targets as Etsy (<a href='https://seekingalpha.com/symbol/ETSY' title='Etsy, Inc.'>ETSY</a> <font color='red'>-6%</font>), Yelp (<a href='https://seekingalpha.com/symbol/YELP' title='Yelp'>YELP</a> <font color='red'>-3.7%</font>), Shutterfly (<a href='https://seekingalpha.com/symbol/SFLY' title='Shutterfly, Inc.'>SFLY</a> <font color='red'>-5.7%</font>), Groupon (<a href='https://seekingalpha.com/symbol/GRPN' title='Groupon, Inc.'>GRPN</a> <font color='red'>-3.5%</font>), GrubHub (<a href='https://seekingalpha.com/symbol/GRUB' title='GrubHub Inc.'>GRUB</a> <font color='red'>-4.1%</font>), Wayfair (<a href='https://seekingalpha.com/symbol/W' title='Wayfair'>W</a> <font color='red'>-9.9%</font>), Snap (<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a> <font color='red'>-5.2%</font>) and Criteo (<a href='https://seekingalpha.com/symbol/CRTO' title='Criteo S.A.'>CRTO</a> <font color='green'>+1.5%</font>). Potential buyers stretch across large cap internet/tech stocks and PE firms.</li><li>The analyst expects activist investors to push eBay (<a href='https://seekingalpha.com/symbol/EBAY' title='eBay Inc.'>EBAY</a> <font color='red'>-1.2%</font>) for the sale of the Classifieds and StubHub businesses. EBAY could use the cash for repurchases and a \"transformative\" acquisition.</li><li>Other predictions/suggestions: IAC (<a href='https://seekingalpha.com/symbol/IAC' title='IAC/InterActiveCorp'>IAC</a> <font color='red'>-4.1%</font>) spinning off Match Group (<a href='https://seekingalpha.com/symbol/MTCH' title='Match Group, Inc.'>MTCH</a> <font color='red'>-4.7%</font>) shares and making a \"large\" acquisition and regulators pressuring Amazon (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='red'>-4.3%</font>) to split in two, though a forced split likely years away.</li><li>Source: Bloomberg First Word.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417623\" data-linked=\"Aegis names internet M&amp;A potentials for 2019\" data-tweet=\"$ETSY $ETSY $YELP - Aegis names internet M&amp;A potentials for 2019 https://seekingalpha.com/news/3417623-aegis-names-internet-m-potentials-for-2019?source=tweet\" data-url=\"https://seekingalpha.com/news/3417623-aegis-names-internet-m-potentials-for-2019\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417622\" data-ts=\"1545076828\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TZOO\" target=\"_blank\">TZOO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417622-ntnx-tzoo-and-bvsn-among-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NTNX, TZOO and BVSN among tech movers</a></h4><ul><li><strong>Gainers: </strong>Travelzoo (NASDAQ:<a href='https://seekingalpha.com/symbol/TZOO' title='Travelzoo Inc'>TZOO</a>) <font color=\"green\">+12%</font>.  Uxin (NASDAQ:<a href='https://seekingalpha.com/symbol/UXIN' title='Uxin'>UXIN</a>) <font color=\"green\">+11%</font>. Upwork (NASDAQ:<a href='https://seekingalpha.com/symbol/UPWK' title='Upwork'>UPWK</a>) <font color=\"green\">+6%</font>. Akoustis Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTS' title='Akoustis Technologies, Inc.'>AKTS</a>) <font color=\"green\">+6%</font>. Gravity (NASDAQ:<a href='https://seekingalpha.com/symbol/GRVY' title='GRAVITY Co., Ltd. - American depositary shares, each representing one'>GRVY</a>) <font color=\"green\">+6%</font>.</li> <li><strong>Losers: </strong>BroadVision (NASDAQ:<a href='https://seekingalpha.com/symbol/BVSN' title='BroadVision, Inc.'>BVSN</a>) <font color=\"red\">-15%</font>. ShotSpotter (NASDAQ:<a href='https://seekingalpha.com/symbol/SSTI' title='ShotSpotter'>SSTI</a>) <font color=\"red\">-14%</font>. SVMK (NASDAQ:<a href='https://seekingalpha.com/symbol/SVMK' title='SurveyMonkey'>SVMK</a>) <font color=\"red\">-12%</font>. Nutanix (NASDAQ:<a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a>) <font color=\"red\">-13%</font>. FTE Networks (NYSEMKT:<a href='https://seekingalpha.com/symbol/FTNW' title='FTE Networks, Inc.'>FTNW</a>) <font color=\"red\">-13%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3417622\" data-linked=\"NTNX, TZOO and BVSN among tech movers\" data-tweet=\"$TZOO $TZOO $UXIN - NTNX, TZOO and BVSN among tech movers https://seekingalpha.com/news/3417622-ntnx-tzoo-and-bvsn-among-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3417622-ntnx-tzoo-and-bvsn-among-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417621\" data-ts=\"1545076735\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XPO\" target=\"_blank\">XPO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417621-xpo-logistics-bounces-back\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XPO Logistics bounces back</a></h4><ul> <li>XPO Logistics (NYSEMKT:<a href='https://seekingalpha.com/symbol/XPO' title='XPO Logistics, Inc'>XPO</a>) is <font color=\"green\">up 4.50%</font> in a comeback bid from last week's decline.</li> <li>Spruce Point Capital issued an <a href=\"https://twitter.com/sprucepointcap/status/1074735003416825856\" target=\"_blank\">update</a> to one of its slides in relation to organic operating cash flow growth, although the firm says the major conclusion of its short report still stands.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3416823-spruce-point-capital-hammers-xpo-logistics\" target=\"_blank\">Spruce Point Capital hammers XPO Logistics</a> (Dec. 13)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3417621\" data-linked=\"XPO Logistics bounces back\" data-tweet=\"$XPO - XPO Logistics bounces back https://seekingalpha.com/news/3417621-xpo-logistics-bounces-back?source=tweet\" data-url=\"https://seekingalpha.com/news/3417621-xpo-logistics-bounces-back\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417619\" data-ts=\"1545076540\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDE\" target=\"_blank\">CDE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417619-gold-gains-stocks-slide-many-precious-metals-miners-post-strong-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold gains as stocks slide; many precious metals miners post strong gains</a></h4><ul><li>Gold futures settle at their <a href=\"https://www.marketwatch.com/story/gold-future-settle-at-a-more-than-1-week-high-2018-12-17\" target=\"_blank\">highest level in more than a week</a>, helped by weakness in the dollar and losses in the stock market; Comex February gold settles <font color=\"green\">+0.8%</font> at $1,251.80/oz.</li><li>\"One of the drivers that is pushing gold higher right now is the flight  to safety [due to lower equities], along with the dollar being sold off a  bit,\" <a href=\"https://www.cnbc.com/2018/12/17/gold-markets-dollar-the-fed-in-focus-.html\" target=\"_blank\">says</a> Michael Matousek, head trader at U.S. Global Investors.</li><li>Investor sentiment toward gold is showing signs of optimism, as speculators switched to a net long position in gold of 10,252 contracts, adding 11,791 contracts in the week to Dec. 11, the first time gold speculators have held a net long position since July.</li><li>Many precious metals miners post large gains in a sea of red for most stocks: <a href='https://seekingalpha.com/symbol/CDE' title='Coeur Mining, Inc.'>CDE</a> <font color=\"green\">+13%</font>, <a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a> <font color=\"green\">+9.6%</font>, <a href='https://seekingalpha.com/symbol/PVG' title='Pretium Resources Inc'>PVG</a> <font color=\"green\">+9.6%</font>, <a href='https://seekingalpha.com/symbol/AGI' title='Alamos Gold Inc'>AGI</a> <font color=\"green\">+9.3%</font>, <a href='https://seekingalpha.com/symbol/AUY' title='Yamana Gold Inc.'>AUY</a> <font color=\"green\">+7.5%</font>, <a href='https://seekingalpha.com/symbol/HL' title='Hecla Mining Co.'>HL</a> <font color=\"green\">+7.4%</font>, <a href='https://seekingalpha.com/symbol/BVN' title='Compañía de Minas Buenaventura S.A.A.'>BVN</a> <font color=\"green\">+7.2%</font>, <a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a> <font color=\"green\">+5.5%</font>, <a href='https://seekingalpha.com/symbol/EXK' title='Endeavour Silver Corp.'>EXK</a> <font color=\"green\">+5%</font>, <a href='https://seekingalpha.com/symbol/KGC' title='Kinross Gold Corporation'>KGC</a> <font color=\"green\">+3.8%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>, <a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a>, <a href='https://seekingalpha.com/symbol/NUGT' title='Direxion Daily Gold Miners Index Bull 3x Shares ETF'>NUGT</a>, <a href='https://seekingalpha.com/symbol/GDXJ' title='VanEck Vectors Junior Gold Miners ETF'>GDXJ</a>, <a href='https://seekingalpha.com/symbol/JNUG' title='Direxion Daily Junior Gold Miners Index Bull 3x Shares ETF'>JNUG</a>, <a href='https://seekingalpha.com/symbol/GGN' title='GAMCO Global Gold, Natural Resources & Income Trust'>GGN</a>, <a href='https://seekingalpha.com/symbol/DUST' title='Direxion Daily Gold Miners Index Bear 3x Shares ETF'>DUST</a>, <a href='https://seekingalpha.com/symbol/IAU' title='iShares Gold Trust ETF'>IAU</a>, <a href='https://seekingalpha.com/symbol/PHYS' title='Sprott Physical Gold Trust'>PHYS</a>, <a href='https://seekingalpha.com/symbol/JDST' title='Direxion Daily Junior Gold Miners Index Bear 3x Shares ETF'>JDST</a>, <a href='https://seekingalpha.com/symbol/SGOL' title='Aberdn Std Gold Shs'>SGOL</a>, <a href='https://seekingalpha.com/symbol/GOEX' title='Global X Gold Explorers ETF'>GOEX</a>, <a href='https://seekingalpha.com/symbol/UGLD' title='VelocityShares 3x Long Gold ETN'>UGLD</a>, <a href='https://seekingalpha.com/symbol/SGDM' title='Sprott Gold Miners ETF'>SGDM</a>, <a href='https://seekingalpha.com/symbol/UGL' title='ProShares Ultra Gold ETF'>UGL</a>, <a href='https://seekingalpha.com/symbol/DGP' title='DB Gold Double Long ETN'>DGP</a>, <a href='https://seekingalpha.com/symbol/GLL' title='ProShares UltraShort Gold ETF'>GLL</a>, <a href='https://seekingalpha.com/symbol/ASA' title='ASA Gold&Precious Metals'>ASA</a>, <a href='https://seekingalpha.com/symbol/GTU' title='Central Gold-Trust'>GTU</a>, <a href='https://seekingalpha.com/symbol/GLDI' title='Credit Suisse Gold Shares Covered Call ETN'>GLDI</a>, <a href='https://seekingalpha.com/symbol/OUNZ' title='VanEck Merk Gold Trust ETF'>OUNZ</a>, <a href='https://seekingalpha.com/symbol/RING' title='iShares MSCI Global Gold Miners ETF'>RING</a>, <a href='https://seekingalpha.com/symbol/DZZ' title='DB Gold Double Short ETN'>DZZ</a>, <a href='https://seekingalpha.com/symbol/SGDJ' title='Sprott Junior Gold Miners ETF'>SGDJ</a>, <a href='https://seekingalpha.com/symbol/DGL' title='Inv DB Mul-Sec Shs Invesco DB Gold Fund'>DGL</a>, <a href='https://seekingalpha.com/symbol/DGLD' title='VelocityShares 3x Inverse Gold ETN'>DGLD</a>, <a href='https://seekingalpha.com/symbol/TGLDX' title='Tocqueville Gold Fund No Load'>TGLDX</a>, <a href='https://seekingalpha.com/symbol/DGZ' title='DB Gold Short ETN'>DGZ</a>, <a href='https://seekingalpha.com/symbol/PSAU' title='Invesco Global Gold and Precious Metals Portfolio ETF'>PSAU</a>, <a href='https://seekingalpha.com/symbol/GOAU' title='U.S. Global GO GOLD and Precious Metal Miners ETF'>GOAU</a>, <a href='https://seekingalpha.com/symbol/GDXX' title='ProShares Ultra Gold Miners ETF'>GDXX</a>, <a href='https://seekingalpha.com/symbol/GYEN' title='AdvisorShares Gartman Gold/Yen ETF'>GYEN</a>, <a href='https://seekingalpha.com/symbol/BAR' title='GraniteShares Gold Trust ETF'>BAR</a>, <a href='https://seekingalpha.com/symbol/GEUR' title='AdvisorShares Gartman Gold/Euro ETF'>GEUR</a>, <a href='https://seekingalpha.com/symbol/GDXS' title='ProShares UltraShort Gold Miners ETF'>GDXS</a>, <a href='https://seekingalpha.com/symbol/GLDW' title='SPDR Long Dollar Gold Trust ETF'>GLDW</a>, <a href='https://seekingalpha.com/symbol/GHS' title='REX Gold Hedged S&P 500 ETF'>GHS</a>, <a href='https://seekingalpha.com/symbol/UBG' title='UBS ETRACS CMCI Gold Total Return ETN'>UBG</a>, <a href='https://seekingalpha.com/symbol/QGLDX' title='The Gold Bullion Strategy Fund Inv'>QGLDX</a>, <a href='https://seekingalpha.com/symbol/GHE' title='REX Gold Hedged FTSE Emerging Markets ETF'>GHE</a>, <a href='https://seekingalpha.com/symbol/MELT' title='Direxion Daily Gold Miners Index Bear 1x Shares ETF'>MELT</a>, <a href='https://seekingalpha.com/symbol/AAAU' title='Perth Mint Physical Gold ETF'>AAAU</a>, <a href='https://seekingalpha.com/symbol/GLDM' title='World Gold Shares SPDR Gold Minishares Trust ETF'>GLDM</a>, <a href='https://seekingalpha.com/symbol/IAUF' title='iShares Gold Strategy ETF'>IAUF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3417619\" data-linked=\"Gold gains as stocks slide; many precious metals miners post strong gains\" data-tweet=\"$CDE $CDE $EGO - Gold gains as stocks slide; many precious metals miners post strong gains https://seekingalpha.com/news/3417619-gold-gains-stocks-slide-many-precious-metals-miners-post-strong-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3417619-gold-gains-stocks-slide-many-precious-metals-miners-post-strong-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417615\" data-ts=\"1545075293\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417615-twitter-resolved-issue-tie-to-state-actors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twitter: Resolved issue could tie to state actors</a></h4><ul><li>Twitter (NYSE:<a href='https://seekingalpha.com/symbol/TWTR' title='Twitter, Inc.'>TWTR</a>) <a href=\"https://www.reuters.com/article/us-twitter-cyber/twitter-says-resolved-issue-that-could-have-exposed-user-country-code-idUSKBN1OG24H\" target=\"_blank\">resolves an issue</a> with one of its complaint forms that could have revealed the country code for a user's phone number associated with the account.</li><li>The issue was fixed on November 16, and the company says it did not expose full phone numbers or other personal information.</li><li>Twitter says it received a large number of enquiries from IP address in China and Saudi Arabia and that \"it is possible that some of these IP addresses may have ties to state-sponsored actors.\u201d</li><li>Twitter shares are <font color=\"red\">down 6%</font> to $33.63.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417615\" data-linked=\"Twitter: Resolved issue could tie to state actors\" data-tweet=\"$TWTR - Twitter: Resolved issue could tie to state actors https://seekingalpha.com/news/3417615-twitter-resolved-issue-tie-to-state-actors?source=tweet\" data-url=\"https://seekingalpha.com/news/3417615-twitter-resolved-issue-tie-to-state-actors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417614\" data-ts=\"1545075284\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTE\" target=\"_blank\">GTE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417614-gran-tierra-energy-hits-record-production-growth-expects-in-2019\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gran Tierra Energy hits record production growth, expects more in 2019</a></h4><ul><li>Gran Tierra Energy (<a href='https://seekingalpha.com/symbol/GTE' title='Gran Tierra Energy, Inc'>GTE</a> <font color='red'>-2.1%</font>) is lower despite announcing <a href=\"https://www.grantierra.com/press-room/article/293-gran-tierra-energy-inc-announces-operational-update-and-2019-guidance-12-to-18-production-growth-within-cash-flow.html\" target=\"_blank\">record production growth</a>, as current output hits 40K boe/day amid what so far is record quarterly production of 38,220 boe/day, up 6% from Q3 and 11% higher than the year-ago period.</li><li>For FY 2019, GTE forecasts production of 40K-42K boe/day, representing organic growth of 12%-18% over the first nine months of 2018 and includes no volumes for any potential exploration success including Pomorroso-1.</li><li>GTE also says it plans a 2019 capital budget of $350M-$370M and forecasts cash flow of $365M-$375M at a $65/bbl Brent oil price.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417614\" data-linked=\"Gran Tierra Energy hits record production growth, expects more in 2019\" data-tweet=\"$GTE - Gran Tierra Energy hits record production growth, expects more in 2019 https://seekingalpha.com/news/3417614-gran-tierra-energy-hits-record-production-growth-expects-in-2019?source=tweet\" data-url=\"https://seekingalpha.com/news/3417614-gran-tierra-energy-hits-record-production-growth-expects-in-2019\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417612\" data-ts=\"1545075185\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COST\" target=\"_blank\">COST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417612-jpmorgan-sticks-costco\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan sticks with Costco</a></h4><ul> <li>JPMorgan takes some lumps for riding into Costco's (<a href='https://seekingalpha.com/symbol/COST' title='Costco Wholesale Corporation'>COST</a> <font color='red'>-1.9%</font>) earnings report with a <a href=\"https://www.barrons.com/articles/costco-stocks-drop-means-its-time-to-buy-jpmorgan-says-51545072515?mod=hp_LATEST\" target=\"_blank\">positive view</a> on the retailer.</li> <li>\"We share the pain of the 8% stock pullback, and acknowledge that our core margin estimates were too high,\" says analyst Chritopher Horvers, who is still positive on the name.</li> <li>\"It\u2019s a consumer staples stock with low tariff risk, so it\u2019s defensive into a slowing consumer environment in 2019, writes Horvers. \"And it is difficult to find mid-single-digit-plus longer term topline growth with very low Amazon.com (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>)/brand risk,\" he adds.</li> <li>Shares of Costco are down 8% over the last three weeks, Analyst sentiment still leans to the bullish side (17 Buy-equivalent ratings, 11 Hold-equivalent ratings, 1 Sell-equivalent rating).</li></ul><div class=\"tiny-share-widget\" data-id=\"3417612\" data-linked=\"JPMorgan sticks with Costco\" data-tweet=\"$COST $COST $AMZN - JPMorgan sticks with Costco https://seekingalpha.com/news/3417612-jpmorgan-sticks-costco?source=tweet\" data-url=\"https://seekingalpha.com/news/3417612-jpmorgan-sticks-costco\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417609\" data-ts=\"1545074618\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JNJ\" target=\"_blank\">JNJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417609-j-and-j-chief-gorsky-defends-talc-powder-shares-remain-under-pressure-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J&amp;J chief Gorsky defends talc powder; shares remain under pressure, down 4%</a></h4><ul><li>In a <a href=\"https://www.jnj.com/latest-news/a-message-from-johnson-johnson-ceo-alex-gorsky-about-talc-safety\" target=\"_blank\">video statement</a>, Johnson &amp; Johnson (<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color=\"red\">-3.9%</font>) Chairman &amp; CEO Alex Gorsky reiterates the company's position that its talc powder is pure, free of contaminants and has not caused cancer or asbestos-related disease. He cites repeated testing over many years by global authorities that has always confirmed the product's integrity and lack of asbestos, adding that the company would have immediately withdrawn the product from the market if it was found to contain such contaminants.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417132-johnson-and-johnson-4-percent-reports-prior-knowledge-asbestos-baby-powder\" target=\"_blank\">Johnson &amp; Johnson down 4% on reports of prior knowledge of asbestos in baby powder</a> (Dec. 14)</li><li><strong>Update</strong>: Reuters <a href=\"https://www.reuters.com/article/us-johnson-johnson-cancer-impact/jj-moves-to-limit-impact-of-reuters-report-on-asbestos-in-baby-powder-idUSKBN1OG2HH\" target=\"_blank\">reports </a>that the company is taking out full-page newspaper ads defending its talc and its business practices.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417609\" data-linked=\"J&amp;J chief Gorsky defends talc powder; shares remain under pressure, down 4%\" data-tweet=\"$JNJ - J&amp;J chief Gorsky defends talc powder; shares remain under pressure, down 4% https://seekingalpha.com/news/3417609-j-and-j-chief-gorsky-defends-talc-powder-shares-remain-under-pressure-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3417609-j-and-j-chief-gorsky-defends-talc-powder-shares-remain-under-pressure-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417604\" data-ts=\"1545073447\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GS\" target=\"_blank\">GS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417604-goldman-defends-saying-was-lied-to-in-1mdb-scandal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman defends itself, saying it was lied to in 1MDB scandal</a></h4><ul><li>Following Malaysia's charges against Goldman Sachs (<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a> <font color='red'>-2.6%</font>) over the 1MDB scandal, the U.S. bank defends itself, saying it <a href=\"https://www.cnbc.com/2018/12/17/goldman-sachs-says-it-was-lied-to-in-1mdb-scandal-that-has-plagued-its-stock.html\" target=\"_blank\">was the victim</a> of deceptive Malaysian officials.</li><li>\"Certain members of the former Malaysian government and 1MDB lied to Goldman Sachs, outside counsel, and others about the use of proceeds from these transactions,\" the bank said in a statement.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417365-malaysia-files-criminal-charges-goldman\" target=\"_blank\">Malaysia files criminal charges against Goldman</a> (Dec. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3417604\" data-linked=\"Goldman defends itself, saying it was lied to in 1MDB scandal\" data-tweet=\"$GS - Goldman defends itself, saying it was lied to in 1MDB scandal https://seekingalpha.com/news/3417604-goldman-defends-saying-was-lied-to-in-1mdb-scandal?source=tweet\" data-url=\"https://seekingalpha.com/news/3417604-goldman-defends-saying-was-lied-to-in-1mdb-scandal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417603\" data-ts=\"1545073104\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDE\" target=\"_blank\">CDE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417603-coeur-mining-and-legacy-reserves-among-energy-materials-gainers-approach-resources-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coeur Mining and Legacy Reserves among Energy/Materials gainers; Approach Resources and Yield10 Bioscience among losers</a></h4><ul><li><b>Gainers: </b>Coeur Mining (NYSE:<a href='https://seekingalpha.com/symbol/CDE' title='Coeur Mining, Inc.'>CDE</a>) <font color=\"green\">+16%</font>. Legacy Reserves (NASDAQ:<a href='https://seekingalpha.com/symbol/LGCY' title='Legacy Reserves Inc'>LGCY</a>) <font color=\"green\">+12%</font>. Pretium Resources (NYSE:<a href='https://seekingalpha.com/symbol/PVG' title='Pretium Resources Inc'>PVG</a>) <font color=\"green\">+10%</font>. Alamos Gold (NYSE:<a href='https://seekingalpha.com/symbol/AGI' title='Alamos Gold Inc'>AGI</a>) <font color=\"green\">+10%</font>. Hecla Mining (NYSE:<a href='https://seekingalpha.com/symbol/HL' title='Hecla Mining Co.'>HL</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>Approach Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/AREX' title='Approach Resources Inc.'>AREX</a>) <font color=\"red\">-12%</font>. Yield10 Bioscience (NASDAQ:<a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a>) <font color=\"red\">-10%</font>. Aceto (NASDAQ:<a href='https://seekingalpha.com/symbol/ACET' title='Aceto Corporation'>ACET</a>) <font color=\"red\">-9%</font>. VAALCO Energy (NYSE:<a href='https://seekingalpha.com/symbol/EGY' title='VAALCO Energy, Inc.'>EGY</a>) <font color=\"red\">-9%</font>. BP Midstream Partners (NYSE:<a href='https://seekingalpha.com/symbol/BPMP' title='BP Midstream Partners LP'>BPMP</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417603\" data-linked=\"Coeur Mining and Legacy Reserves among Energy/Materials gainers; Approach Resources and Yield10 Bioscience among losers\" data-tweet=\"$CDE $CDE $LGCY - Coeur Mining and Legacy Reserves among Energy/Materials gainers; Approach Resources and Yield10 Bioscience among losers https://seekingalpha.com/news/3417603-coeur-mining-and-legacy-reserves-among-energy-materials-gainers-approach-resources-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3417603-coeur-mining-and-legacy-reserves-among-energy-materials-gainers-approach-resources-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417600\" data-ts=\"1545072811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417600-activist-investor-urges-clovis-to-pursue-sale-shares-down-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Activist investor urges Clovis to pursue sale; shares down 9%</a></h4><ul><li>Bloomberg <a href=\"https://www.bloomberg.com/news/articles/2018-12-17/activist-is-said-to-push-cancer-drugmaker-clovis-to-pursue-sale\" target=\"_blank\">reports </a>that activist investor Armistice Capital LLC has been urging Clovis Oncology (<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color=\"red\">-8.8%</font>) to pursue a sale in the wake of GlaxoSmithKline's $5.1B bid for PARP competitor TESARO (<a href='https://seekingalpha.com/symbol/TSRO' title='Tesaro'>TSRO</a> <font color=\"green\">+0.1%</font>) despite the expectations that its PARP inhibitor Zejula (niraparib) is not expected to reach the $1B sales mark until 2023, hardly a surprising move by the owner of a 9.8% stake in CLVS who wants to avoid a potential loss.</li><li>Clovis' Rubraca (rucaparib) is supposed to be a blockbuster as well but it has generated only $82M in sales over the past four quarters.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417600\" data-linked=\"Activist investor urges Clovis to pursue sale; shares down 9%\" data-tweet=\"$CLVS $CLVS $TSRO - Activist investor urges Clovis to pursue sale; shares down 9% https://seekingalpha.com/news/3417600-activist-investor-urges-clovis-to-pursue-sale-shares-down-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3417600-activist-investor-urges-clovis-to-pursue-sale-shares-down-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417594\" data-ts=\"1545070472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVR\" target=\"_blank\">NVR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417594-homebuilder-stocks-gain-voices-call-for-fed-to-halt-hikes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Homebuilder stocks gain as voices call for Fed to halt hikes</a></h4><ul><li>Most homebuilders are in the green in early afternoon as President Trump, his trade adviser <a href=\"https://www.bloomberg.com/news/articles/2018-12-17/navarro-blasts-case-for-fed-rate-hike-to-defend-its-independence?utm_campaign=socialflow-organic&amp;utm_source=twitter&amp;utm_content=business&amp;cmpid=socialflow-twitter-business&amp;utm_medium=social\" target=\"_blank\">Peter Navarro</a>, and investor Jeffrey Gundlach agree that the Fed's FOMC shouldn't increase interest rates when they meet later this week.</li><li>iShares Dow Jones US Home Construction ETF (BATS:<a href='https://seekingalpha.com/symbol/ITB' title='iShares U.S. Home Construction ETF'>ITB</a>) <font color=\"green\">rises 0.1% </font>compared with the S&amp;P 500 <font color=\"red\">declining 1.0%</font>.</li><li>Among individual homebuilding names: NVR (<a href='https://seekingalpha.com/symbol/NVR' title='NVR, Inc.'>NVR</a> <font color=\"green\">+1.3%</font>), Toll Brothers (<a href='https://seekingalpha.com/symbol/TOL' title='Toll Brothers Inc.'>TOL</a> <font color=\"green\">+0.7%</font>), PulteGroup (<a href='https://seekingalpha.com/symbol/PHM' title='PulteGroup, Inc.'>PHM</a> <font color=\"green\">+0.9%</font>), Lennar (<a href='https://seekingalpha.com/symbol/LEN' title='Lennar Corporation'>LEN</a> <font color=\"green\">+0.3%</font>), and TRI Pointe Homes (<a href='https://seekingalpha.com/symbol/TPH' title='TRI Pointe Group, Inc.'>TPH</a> <font color=\"green\">+2.3%</font>).</li><li>Earlier today,<a href=\"https://seekingalpha.com/news/3417500-nahb-housing-market-index-unexpectedly-tumbles-december\" target=\"_blank\"> NAHB Housing Market Index</a> of 56 falls short of consensus of 61 and slips from November's reading of 60.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417575-gundlach-says-fed-hike-pretty-sure-stocks-bear-territory\" target=\"_blank\">Gundlach says Fed shouldn't hike, \"pretty sure\" stocks are in bear territory</a> (Dec. 17)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XHB' title='SPDR Homebuilders ETF'>XHB</a>, <a href='https://seekingalpha.com/symbol/ITB' title='iShares U.S. Home Construction ETF'>ITB</a>, <a href='https://seekingalpha.com/symbol/PKB' title='Invesco Dynamic Building & Construction Portfolio ETF'>PKB</a>, <a href='https://seekingalpha.com/symbol/NAIL' title='Direxion Daily Homebuilders & Supplies Bull 3x Shares ETF'>NAIL</a>, <a href='https://seekingalpha.com/symbol/HOML' title='ETRACS Monthly Reset 2xLeveraged ISE Exclusively Homebuilders ETN'>HOML</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3417594\" data-linked=\"Homebuilder stocks gain as voices call for Fed to halt hikes\" data-tweet=\"$NVR $ITB $NVR - Homebuilder stocks gain as voices call for Fed to halt hikes https://seekingalpha.com/news/3417594-homebuilder-stocks-gain-voices-call-for-fed-to-halt-hikes?source=tweet\" data-url=\"https://seekingalpha.com/news/3417594-homebuilder-stocks-gain-voices-call-for-fed-to-halt-hikes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417593\" data-ts=\"1545070386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCD\" target=\"_blank\">MCD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417593-chick-fil-gobbles-up-market-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chick-fil-A gobbles up more market share</a></h4><ul> <li>Chick-fil-A sales are up 15.5% this year on a double-digit traffic gain, according to <a href=\"https://www.marketwatch.com/story/as-chick-fil-a-surges-mcdonalds-and-wendys-are-under-threat-2018-12-17\" target=\"_blank\">data</a> from Restaurant Business. The continued momentum for the chain has it on the verge of passing Subway to become the third largest restaurant concept in the U.S. as it continues to nab market share from McDonald's (<a href='https://seekingalpha.com/symbol/MCD' title='McDonald&#39;s Corporation'>MCD</a> <font color='red'>-0.5%</font>), Burger King (<a href='https://seekingalpha.com/symbol/QSR' title='Restaurant Brands International Inc.'>QSR</a> <font color='red'>-1.3%</font>), Taco Bell (<a href='https://seekingalpha.com/symbol/YUM' title='Yum! Brands, Inc.'>YUM</a> <font color='red'>-1.6%</font>), Wendy's (<a href='https://seekingalpha.com/symbol/WEN' title='The Wendy&#39;s Company'>WEN</a> <font color='red'>-1.9%</font>) and others.</li> <li>\"We have long pointed out that Chick-fil-A is the restaurant competition with which McDonald\u2019s U.S. should most concern itself \u2013 and by extension, investors should too,\" notes Kalinowski Research analysts.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3417593\" data-linked=\"Chick-fil-A gobbles up more market share\" data-tweet=\"$MCD $MCD $QSR - Chick-fil-A gobbles up more market share https://seekingalpha.com/news/3417593-chick-fil-gobbles-up-market-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3417593-chick-fil-gobbles-up-market-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417587\" data-ts=\"1545069520\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LION\" target=\"_blank\">LION</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417587-fidelity-southern-leads-financial-gainers-first-capital-and-colony-capital-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fidelity Southern leads financial gainers; First Capital and Colony Capital among losers</a></h4><ul><li><b>Gainers:</b> Fidelity Southern (NASDAQ:<a href='https://seekingalpha.com/symbol/LION' title='Fidelity Southern Corporation'>LION</a>) <font color=\"green\">+20%</font>. Ocwen Financial (NYSE:<a href='https://seekingalpha.com/symbol/OCN' title='Ocwen Financial Corporation'>OCN</a>) <font color=\"green\">+10%</font>. KCAP Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/KCAP' title='KCAP Financial'>KCAP</a>) <font color=\"green\">+9%</font>. InnSuites Hospitality Trust (NYSEMKT:<a href='https://seekingalpha.com/symbol/IHT' title='Innsuites Hospitality Trust'>IHT</a>) <font color=\"green\">+6%</font>. LM Funding America (NASDAQ:<a href='https://seekingalpha.com/symbol/LMFA' title='LM Funding America, Inc.'>LMFA</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers:</b> Wheeler Real Estate Investment Trust (NASDAQ:<a href='https://seekingalpha.com/symbol/WHLR' title='Wheeler Real Estate Investment Trust'>WHLR</a>) <font color=\"red\">-13%</font>. Cedar Realty Trust (NYSE:<a href='https://seekingalpha.com/symbol/CDR' title='Cedar Realty Trust, Inc.'>CDR</a>) <font color=\"red\">-9%</font>. PPDAI Group (NYSE:<a href='https://seekingalpha.com/symbol/PPDF' title='PPDAI Group Inc.'>PPDF</a>) <font color=\"red\">-9%</font>. First Capital (NASDAQ:<a href='https://seekingalpha.com/symbol/FCAP' title='First Capital, Inc.'>FCAP</a>) <font color=\"red\">-8%</font>. Colony Capital (NYSE:<a href='https://seekingalpha.com/symbol/CLNY' title='Colony Capital, Inc.'>CLNY</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417587\" data-linked=\"Fidelity Southern leads financial gainers; First Capital and Colony Capital among losers\" data-tweet=\"$LION $LION $OCN - Fidelity Southern leads financial gainers; First Capital and Colony Capital among losers https://seekingalpha.com/news/3417587-fidelity-southern-leads-financial-gainers-first-capital-and-colony-capital-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3417587-fidelity-southern-leads-financial-gainers-first-capital-and-colony-capital-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417584\" data-ts=\"1545068980\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DFFN\" target=\"_blank\">DFFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417584-microcaps-mostly-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps mostly among midday movers</a></h4><ul><li><strong>Gainers: </strong>Diffusion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a>) <font color=\"green\">+42%</font>. NRC Group Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/NRCG' title='NRC Group Holdings Corp'>NRCG</a>) <font color=\"green\">+22%</font>. Fidelity Southern (NASDAQ:<a href='https://seekingalpha.com/symbol/LION' title='Fidelity Southern Corporation'>LION</a>) <font color=\"green\">+21%</font>. HyreCar (NASDAQ:<a href='https://seekingalpha.com/symbol/HYRE' title='HyreCar'>HYRE</a>) <font color=\"green\">+18%</font>. YRC Worldwide (NASDAQ:<a href='https://seekingalpha.com/symbol/YRCW' title='YRC Worldwide, Inc.'>YRCW</a>) <font color=\"green\">+19%</font>. Axovant Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a>) <font color=\"green\">+17%</font>. AgeX Therapeutics (NYSEMKT:<a href='https://seekingalpha.com/symbol/AGE' title='AgeX Therapeutics Inc'>AGE</a>) <font color=\"green\">+15%</font>. Coeur Mining (NYSE:<a href='https://seekingalpha.com/symbol/CDE' title='Coeur Mining, Inc.'>CDE</a>) <font color=\"green\">+15%</font>. Travelzoo (NASDAQ:<a href='https://seekingalpha.com/symbol/TZOO' title='Travelzoo Inc'>TZOO</a>) <font color=\"green\">+14%</font>. Legacy Reserves (NASDAQ:<a href='https://seekingalpha.com/symbol/LGCY' title='Legacy Reserves Inc'>LGCY</a>) <font color=\"green\">+13%</font>.</li> <li><strong>Losers: </strong>Sophiris Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/SPHS' title='Sophiris Bio'>SPHS</a>) <font color=\"red\">-41%</font>. Dova Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DOVA' title='Dova Pharmaceuticals'>DOVA</a>) <font color=\"red\">-31%</font>. ReTo Eco-Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/RETO' title='RETO Eco-Solutions'>RETO</a>) <font color=\"red\">-21%</font>. Adial Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADIL' title='ADial Pharmaceuticals, Inc'>ADIL</a>) <font color=\"red\">-21%</font>. Overstock.com (NASDAQ:<a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>) <font color=\"red\">-20%</font>. NF Energy Saving (NASDAQ:<a href='https://seekingalpha.com/symbol/NFEC' title='NF Energy Saving Corp.'>NFEC</a>) <font color=\"red\">-19%</font>. SPI Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/SPI' title='SPI Energy Co., Ltd.'>SPI</a>) <font color=\"red\">-18%</font>. Meili (NYSE:<a href='https://seekingalpha.com/symbol/MOGU' title='MOGU'>MOGU</a>) <font color=\"red\">-16%</font>. Aileron Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALRN' title='Aileron Therapeutics'>ALRN</a>) <font color=\"red\">-15%</font>. Achillion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a>) <font color=\"red\">-15%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3417584\" data-linked=\"Microcaps mostly among midday movers\" data-tweet=\"$DFFN $DFFN $NRCG - Microcaps mostly among midday movers https://seekingalpha.com/news/3417584-microcaps-mostly-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3417584-microcaps-mostly-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417582\" data-ts=\"1545068919\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPR\" target=\"_blank\">TPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417582-wells-fargo-defends-retail\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells Fargo defends retail</a></h4><ul> <li>Wells Fargo checks in on the retail sector amid the \"wall of worry\" that seems to be piling up.</li> <li>\"While there are many potential reasons for the sell-off (concerns about potentially slowing growth/tough compares, uncertainty around China, the never-ending e-commerce threat, etc.) - we think it\u2019s interesting that recent fundamentals have actually been decent,\" writes the WF analyst team.</li> <li>\"Basically, 3Q comps on average across our space were in the +2-3% range (for the 4th quarter in a row), and early reads on Holiday gave actually been relatively solid (especially Black Friday).\"</li> <li>After a tactical look at retail stocks by Wells - Tapestry (<a href='https://seekingalpha.com/symbol/TPR' title='Tapestry, Inc.'>TPR</a> <font color='green'>+0.9%</font>), Lululemon (<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a> <font color='green'>+1.1%</font>), Carter's (<a href='https://seekingalpha.com/symbol/CRI' title='Carter&#39;s, Inc.'>CRI</a> <font color='red'>-0.7%</font>), L Brands (<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a> <font color='red'>-2.3%</font>) and Foot Locker (<a href='https://seekingalpha.com/symbol/FL' title='Foot Locker, Inc.'>FL</a> <font color='red'>-1.2%</font>) emerge as interesting picks amid the weakness.</li><li>Some of today's largest decliners are Farfetch (<a href='https://seekingalpha.com/symbol/FTCH' title='Farfetch'>FTCH</a> <font color='red'>-10.8%</font>), Stitch Fix (<a href='https://seekingalpha.com/symbol/SFIX' title='Stitch Fix, Inc.'>SFIX</a> <font color='red'>-5.8%</font>), Duluth Holdings (<a href='https://seekingalpha.com/symbol/DLTH' title='Duluth Holdings'>DLTH</a> <font color='red'>-4.8%</font>), Tailored Brands (<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc'>TLRD</a> <font color='red'>-4.3%</font>), Shoe Carnival (<a href='https://seekingalpha.com/symbol/SCVL' title='Shoe Carnival, Inc.'>SCVL</a> <font color='red'>-3.4%</font>), Boot Barn (<a href='https://seekingalpha.com/symbol/BOOT' title='Boot Barn Holdings'>BOOT</a> <font color='red'>-3.6%</font>), Williams-Sonoma (<a href='https://seekingalpha.com/symbol/WSM' title='Williams-Sonoma Inc.'>WSM</a> <font color='red'>-2.6%</font>) and Target (<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a> <font color='red'>-2.6%</font>).</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLY' title='Consumer Discretionary Select Sector SPDR ETF'>XLY</a>, <a href='https://seekingalpha.com/symbol/XRT' title='SPDR S&P Retail ETF'>XRT</a>, <a href='https://seekingalpha.com/symbol/VCR' title='Vanguard Consumer Discretionary ETF'>VCR</a>, <a href='https://seekingalpha.com/symbol/RTH' title='VanEck Vectors Retail ETF'>RTH</a>, <a href='https://seekingalpha.com/symbol/RETL' title='Direxion Daily Retail Bull 3x Shares ETF'>RETL</a>, <a href='https://seekingalpha.com/symbol/FDIS' title='Fidelity MSCI Consumer Discretionary Index ETF'>FDIS</a>, <a href='https://seekingalpha.com/symbol/IYK' title='iShares U.S. Consumer Goods ETF'>IYK</a>, <a href='https://seekingalpha.com/symbol/FXD' title='First Trust Consumer Discretionary AlphaDEX ETF'>FXD</a>, <a href='https://seekingalpha.com/symbol/EMTY' title='ProShares Decline of the Retail Store ETF'>EMTY</a>, <a href='https://seekingalpha.com/symbol/RCD' title='Invesco S&P Equal Weight Consumer Discretionary ETF'>RCD</a>, <a href='https://seekingalpha.com/symbol/PMR' title='Invesco Dynamic Retail Portfolio ETF'>PMR</a>, <a href='https://seekingalpha.com/symbol/UGE' title='ProShares Ultra Consumer Goods ETF'>UGE</a>, <a href='https://seekingalpha.com/symbol/SZK' title='ProShares UltraShort Consumer Goods ETF'>SZK</a>, <a href='https://seekingalpha.com/symbol/FTXD' title='First Trust Nasdaq Retail ETF'>FTXD</a>, <a href='https://seekingalpha.com/symbol/JHMC' title='John Hancock Multifactor Consumer Discretionary ETF'>JHMC</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3417582\" data-linked=\"Wells Fargo defends retail\" data-tweet=\"$TPR $TPR $LULU - Wells Fargo defends retail https://seekingalpha.com/news/3417582-wells-fargo-defends-retail?source=tweet\" data-url=\"https://seekingalpha.com/news/3417582-wells-fargo-defends-retail\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417581\" data-ts=\"1545068858\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URGN\" target=\"_blank\">URGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417581-urogen-launches-rolling-submission-of-u-s-marketing-application-for-ugnminus-101-shares-up-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UroGen launches rolling submission of U.S. marketing application for UGN-101; shares up 5%</a></h4><ul><li>Thinly traded UroGen Pharma (<a href='https://seekingalpha.com/symbol/URGN' title='UroGen Pharma'>URGN</a> <font color=\"green\">+4.6%</font>) is up on average volume in response to its <a href=\"https://seekingalpha.com/pr/17359577-urogen-pharma-initiates-rolling-submission-new-drug-application-nda-ugnminus-101-treatment\" target=\"_blank\">announcement </a>that it has initiated the rolling submission of its U.S. marketing application seeking approval for Orphan Drug- and Breakthrough Therapy-tagged UGN-101 (mitomycin gel) for the treatment of patients with low-grade upper tract urothelial cancer. It expects to complete the filing by mid-2019 and hopes to get the FDA nod by late 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417581\" data-linked=\"UroGen launches rolling submission of U.S. marketing application for UGN-101; shares up 5%\" data-tweet=\"$URGN - UroGen launches rolling submission of U.S. marketing application for UGN-101; shares up 5% https://seekingalpha.com/news/3417581-urogen-launches-rolling-submission-of-u-s-marketing-application-for-ugnminus-101-shares-up-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3417581-urogen-launches-rolling-submission-of-u-s-marketing-application-for-ugnminus-101-shares-up-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417579\" data-ts=\"1545068493\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYRX\" target=\"_blank\">CYRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417579-cryoport-announces-25m-investment-from-petrichor-shares-up-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CryoPort announces $25M investment from Petrichor; shares up 8%</a></h4><ul><li>Thinly traded micro cap Cryoport (<a href='https://seekingalpha.com/symbol/CYRX' title='CryoPort, Inc.'>CYRX</a> <font color=\"green\">+7.8%</font>) is up on below-average volume following its <a href=\"https://seekingalpha.com/pr/17359721-cryoport-announces-25-million-investment-petrichor-healthcare-capital-management\" target=\"_blank\">announcement </a>that Petrichor Healthcare Capital Management has invested $25M in the company.</li><li>Petrichor bought 1M common shares at $10 per share plus funded a $15M note convertible into common shares at $13.11 per share. The interest rate on the five-year instrument is 3-month LIBOR plus 6%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417579\" data-linked=\"CryoPort announces $25M investment from Petrichor; shares up 8%\" data-tweet=\"$CYRX - CryoPort announces $25M investment from Petrichor; shares up 8% https://seekingalpha.com/news/3417579-cryoport-announces-25m-investment-from-petrichor-shares-up-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3417579-cryoport-announces-25m-investment-from-petrichor-shares-up-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417570\" data-ts=\"1545067030\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GD\" target=\"_blank\">GD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417570-general-dynamics-slips-trudeau-says-canada-may-nix-saudi-arms-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">General Dynamics slips as Trudeau says Canada may nix Saudi arms deal</a></h4><ul><li>General Dynamics (<a href='https://seekingalpha.com/symbol/GD' title='General Dynamics Corporation'>GD</a> <font color=\"red\">-1.6%</font>) is lower after Canadian Prime Minister Trudeau said for the first time that his government was <a href=\"https://www.reuters.com/article/us-saudi-khashoggi-canada/canada-is-looking-for-a-way-out-of-big-saudi-arms-deal-says-pm-idUSKBN1OF0VX\" target=\"_blank\">looking for a way out</a> of a multibillion-dollar arms deal with Saudi Arabia.</li><li>The comments reflected a tougher tone from Trudeau, who previously talked about penalties for scrapping the $13B agreement for armored vehicles made by GD's Canadian unit.</li><li>\u201cWe are engaged with the export permits to try and see if there is a way of no longer exporting these vehicles to Saudi Arabia,\u201d Trudeau said in a televised interview over the weekend, without offering further details.</li><li>Political opponents, citing the killing of journalist Jamal Khashoggi and Saudi Arabia\u2019s involvement in the Yemen war, say Trudeau should end the GD deal, which was negotiated by the previous government.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417570\" data-linked=\"General Dynamics slips as Trudeau says Canada may nix Saudi arms deal\" data-tweet=\"$GD - General Dynamics slips as Trudeau says Canada may nix Saudi arms deal https://seekingalpha.com/news/3417570-general-dynamics-slips-trudeau-says-canada-may-nix-saudi-arms-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3417570-general-dynamics-slips-trudeau-says-canada-may-nix-saudi-arms-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417567\" data-ts=\"1545066556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BGNE\" target=\"_blank\">BGNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417567-beigenes-tislelizumab-shows-positive-action-in-early-stage-cancer-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BeiGene&#39;s tislelizumab shows positive action in early-stage cancer study</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17359251-beigene-announces-updated-phase-1a-1b-data-tislelizumab-presented-european-society-medical\" target=\"_blank\">Updated data </a>from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02407990?term=NCT02407990&amp;rank=1\" target=\"_blank\">Phase 1a/1b clinical trial</a> evaluating BeiGene's (<a href='https://seekingalpha.com/symbol/BGNE' title='BeiGene'>BGNE</a> <font color=\"green\">+2%</font>) anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors continue to show a treatment benefit. The results were presented at the ESMO Immuno-Oncology Congress in Geneva.</li><li>The confirmed response rate was 29.4% (n=5/17), including one complete responder in 17 patients with urothelial carcinoma. Three additional patients experienced stable cancer implying a disease control rate &#40;DCR&#41; of 47.1% (n=8/17). Median duration of response was 18.7 months.</li><li>The response rate and DCR in patients with esophageal cancer were 11.1% and 37.0%, respectively. In gastric cancer patients, the response rate and DCR were 12.2% and 51.0%, respectively. In non-small lung cancer &#40;NSCLC&#41;, the rates were 13.0% and 63.0%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417567\" data-linked=\"BeiGene&#39;s tislelizumab shows positive action in early-stage cancer study\" data-tweet=\"$BGNE - BeiGene&#39;s tislelizumab shows positive action in early-stage cancer study https://seekingalpha.com/news/3417567-beigenes-tislelizumab-shows-positive-action-in-early-stage-cancer-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3417567-beigenes-tislelizumab-shows-positive-action-in-early-stage-cancer-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417564\" data-ts=\"1545066324\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPI\" target=\"_blank\">SPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417564-spi-energyminus-18-on-nasdaq-delinquency-notice\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SPI Energy -18% on Nasdaq delinquency notice</a></h4><ul><li>SPI Energy (<a href='https://seekingalpha.com/symbol/SPI' title='SPI Energy Co., Ltd.'>SPI</a> <font color='red'>-18.2%</font>) plunges after Nasdaq informs the company that it is <a href=\"https://seekingalpha.com/pr/17359355-spi-energy-co-ltd-announces-receipt-delinquency-notice-nasdaq\" target=\"_blank\">not in compliance</a> with continued listing standards because its market cap totaled less than $15M.</li><li>SPI says it is not eligible for the typical 180-day compliance period because the Nasdaq hearings panel earlier had determined to impose a panel monitor lasting through 2019.</li><li>SPI says the panel  noted that if at any time during the monitor period the company fails  any listing standard, Nasdaq would issue a delisting determination and schedule a new hearing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417564\" data-linked=\"SPI Energy -18% on Nasdaq delinquency notice\" data-tweet=\"$SPI - SPI Energy -18% on Nasdaq delinquency notice https://seekingalpha.com/news/3417564-spi-energyminus-18-on-nasdaq-delinquency-notice?source=tweet\" data-url=\"https://seekingalpha.com/news/3417564-spi-energyminus-18-on-nasdaq-delinquency-notice\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417563\" data-ts=\"1545066279\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBEV\" target=\"_blank\">NBEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417563-new-age-beverages-and-tata-motors-among-consumer-gainers-orchids-paper-products-and-davidstea\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Age Beverages and Tata Motors among consumer gainers; Orchids Paper Products and DAVIDsTEA among losers</a></h4><ul><li><b>Gainers: </b>New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) <font color=\"green\">+10%</font>. Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp. Ltd.'>SOLO</a>) <font color=\"green\">+8%</font>. Cryoport (NASDAQ:<a href='https://seekingalpha.com/symbol/CYRX' title='CryoPort, Inc.'>CYRX</a>) <font color=\"green\">+8%</font>. Tata Motors (NYSE:<a href='https://seekingalpha.com/symbol/TTM' title='Tata Motors Limited'>TTM</a>) <font color=\"green\">+5%</font>. Dana (NYSE:<a href='https://seekingalpha.com/symbol/DAN' title='Dana, Inc.'>DAN</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Xcel Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/XELB' title='Xcel Brands, Inc.'>XELB</a>) <font color=\"red\">-11%</font>. Orchids Paper Products (NYSEMKT:<a href='https://seekingalpha.com/symbol/TIS' title='Orchids Paper Products Company'>TIS</a>) <font color=\"red\">-7%</font>. NIO (NYSE:<a href='https://seekingalpha.com/symbol/NIO' title='NIO'>NIO</a>) <font color=\"red\">-6%</font>. Farmmi (NASDAQ:<a href='https://seekingalpha.com/symbol/FAMI' title='Farmmi Inc.'>FAMI</a>) <font color=\"red\">-6%</font>. DAVIDsTEA (NASDAQ:<a href='https://seekingalpha.com/symbol/DTEA' title='DAVIDs TEA'>DTEA</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417563\" data-linked=\"New Age Beverages and Tata Motors among consumer gainers; Orchids Paper Products and DAVIDsTEA among losers\" data-tweet=\"$NBEV $NBEV $SOLO - New Age Beverages and Tata Motors among consumer gainers; Orchids Paper Products and DAVIDsTEA among losers https://seekingalpha.com/news/3417563-new-age-beverages-and-tata-motors-among-consumer-gainers-orchids-paper-products-and-davidstea?source=tweet\" data-url=\"https://seekingalpha.com/news/3417563-new-age-beverages-and-tata-motors-among-consumer-gainers-orchids-paper-products-and-davidstea\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417562\" data-ts=\"1545065711\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPL\" target=\"_blank\">LPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417562-lg-will-boost-oled-output-40-in-2019\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LG will boost OLED output 40% in 2019</a></h4><ul><li>LG Display (NYSE:<a href='https://seekingalpha.com/symbol/LPL' title='LG Display Co., Ltd.'>LPL</a>) will boost its total OLED output by 4M units (+40% Y/Y) next year, according to <em><a href=\"https://asia.nikkei.com/Business/Business-Trends/Japan-manufacturers-OLED-TV-sales-poised-to-top-1m-in-2019\" target=\"_blank\">Nikkei Asian Review</a></em>. <ul><li>The company wants to sell 850K panels to Sony and 300K to Panasonic versus the estimated 500K and 200K, respectively, this year.</li></ul></li><li><ul><li>LPL is <font color=\"green\">up 2%</font> to $8.05.</li></ul></li></ul><div class=\"tiny-share-widget\" data-id=\"3417562\" data-linked=\"LG will boost OLED output 40% in 2019\" data-tweet=\"$LPL - LG will boost OLED output 40% in 2019 https://seekingalpha.com/news/3417562-lg-will-boost-oled-output-40-in-2019?source=tweet\" data-url=\"https://seekingalpha.com/news/3417562-lg-will-boost-oled-output-40-in-2019\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417557\" data-ts=\"1545065389\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAH\" target=\"_blank\">SAH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417557-auto-retailers-break-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Auto retailers break higher</a></h4><ul> <li>Auto retailers are outperforming the market on the day, led by a <font color=\"green\">5.8% jump</font> for Sonic Automotive (NYSE:<a href='https://seekingalpha.com/symbol/SAH' title='Sonic Automotive Inc.'>SAH</a>) off its 52-week low.</li><li>Traders says attractive valuation and some M&amp;A potential in the sector is helping to lift sentiment.</li> <li>Carvana (<a href='https://seekingalpha.com/symbol/CVNA' title='Carvana Co.'>CVNA</a> <font color=\"green\">+4.2%</font>), Group 1 Automotive (<a href='https://seekingalpha.com/symbol/GPI' title='Group 1 Automotive Inc.'>GPI</a> <font color=\"green\">+3.8%</font>), Rush Enterprises (<a href='https://seekingalpha.com/symbol/RUSHA' title='Rush Enterprises, Inc.'>RUSHA</a> <font color=\"green\">+3.2%</font>), AutoNation (<a href='https://seekingalpha.com/symbol/AN' title='AutoNation Inc'>AN</a> <font color=\"green\">+2.8%</font>) and Lithia Motors (<a href='https://seekingalpha.com/symbol/LAD' title='Lithia Motors, Inc.'>LAD</a> <font color=\"green\">+3.1%</font>) are also higher on the day.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3417557\" data-linked=\"Auto retailers break higher\" data-tweet=\"$SAH $SAH $CVNA - Auto retailers break higher https://seekingalpha.com/news/3417557-auto-retailers-break-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3417557-auto-retailers-break-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417556\" data-ts=\"1545065157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTRP\" target=\"_blank\">NTRP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417556-neurotrope-down-2-on-direct-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neurotrope down 2% on direct equity offering</a></h4><ul><li>Ultra-thinly traded nano cap Neurotrope (<a href='https://seekingalpha.com/symbol/NTRP' title='Neurotrope, Inc.'>NTRP</a> <font color=\"red\">-1.6%</font>) is down on a 4x surge in volume, albeit on turnover of only 66K shares, in reaction to its <a href=\"https://seekingalpha.com/pr/17359900-neurotrope-announces-22_5-million-registered-direct-offering\" target=\"_blank\">direct offering</a> of ~5M shares of common stock and five-year warrants to purchase up to the same number of shares at a combined price of $4.495. Gross proceeds will be ~$22.5M. Closing date is December 19.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417556\" data-linked=\"Neurotrope down 2% on direct equity offering\" data-tweet=\"$NTRP - Neurotrope down 2% on direct equity offering https://seekingalpha.com/news/3417556-neurotrope-down-2-on-direct-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3417556-neurotrope-down-2-on-direct-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417553\" data-ts=\"1545064637\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LYB\" target=\"_blank\">LYB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417553-lyondellbasell-upgraded-to-buy-deutsche-bank-seeing-short-downturn\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LyondellBasell upgraded to Buy at Deutsche Bank, seeing short downturn</a></h4><ul><li>LyondellBasell (<a href='https://seekingalpha.com/symbol/LYB' title='LyondellBasell Industries N.V.'>LYB</a> <font color='green'>+1.7%</font>) moves higher after Deutsche Bank <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Deutsche+Bank+Upgrades+LyondellBasell+Industries+%28LYB%29+to+Buy/14927318.html\" target=\"_blank\">upgrades shares to Buy</a> from Hold with a $95 price target, expecting the ethylene cycle downturn to be short and shallow as LYB is trading at the low end of the peak earnings range for commodity chemical stocks.</li><li>LYB sells for just 7.5x 2019 EPS vs. a historical 7x-10x peak earnings range, DB analyst David Begleiter says, adding that LYB's 4.9% dividend yield mitigates the risk of being early while getting \"paid to wait.\"</li><li>Begleiter also believes LYB's Braskem acquisition would be immediately accretive without placing undue stress on the balance sheet.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417553\" data-linked=\"LyondellBasell upgraded to Buy at Deutsche Bank, seeing short downturn\" data-tweet=\"$LYB - LyondellBasell upgraded to Buy at Deutsche Bank, seeing short downturn https://seekingalpha.com/news/3417553-lyondellbasell-upgraded-to-buy-deutsche-bank-seeing-short-downturn?source=tweet\" data-url=\"https://seekingalpha.com/news/3417553-lyondellbasell-upgraded-to-buy-deutsche-bank-seeing-short-downturn\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417547\" data-ts=\"1545064352\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABC\" target=\"_blank\">ABC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417547-drug-distributors-under-modest-pressure-after-60-minutes-opioid-piece\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Drug distributors under modest pressure after 60 Minutes opioid piece</a></h4><ul><li>AmerisourceBergen (<a href='https://seekingalpha.com/symbol/ABC' title='AmerisourceBergen Corporation'>ABC</a> <font color=\"red\">-1%</font>), McKesson (<a href='https://seekingalpha.com/symbol/MCK' title='McKesson Corporation'>MCK</a> <font color=\"red\">-1.3%</font>) and Cardinal Health (<a href='https://seekingalpha.com/symbol/CAH' title='Cardinal Health Inc.'>CAH</a> <font color=\"red\">-2.1%</font>) are all in the red on below-average volume. Last night, 60 Minutes ran a piece on the opioid crisis, its second, in which the most prominent plaintiff attorney said that drug distributors have played a major role in the crisis by looking the other way regarding excessive shipments of opioid painkillers to small pharmacies in heavily affected areas like Ohio and West Virginia.</li><li>In a <a href=\"https://www.mckesson.com/about-mckesson/fighting-opioid-abuse/60-minutes-response/\" target=\"_blank\">statement</a>, McKesson calls the piece \"one-sided\" since it ignores the doctors who prescribe the drugs, the government agencies that license pharmacies, insurers that pay for the drugs and the DEA who sets the quotas, adding the many of the overdose deaths in the U.S. were due to illegal drugs, not prescription medications.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417547\" data-linked=\"Drug distributors under modest pressure after 60 Minutes opioid piece\" data-tweet=\"$ABC $ABC $MCK - Drug distributors under modest pressure after 60 Minutes opioid piece https://seekingalpha.com/news/3417547-drug-distributors-under-modest-pressure-after-60-minutes-opioid-piece?source=tweet\" data-url=\"https://seekingalpha.com/news/3417547-drug-distributors-under-modest-pressure-after-60-minutes-opioid-piece\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417546\" data-ts=\"1545064301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ELY\" target=\"_blank\">ELY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417546-roth-capital-turns-cautious-on-callaway-golf\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roth Capital turns cautious on Callaway Golf</a></h4><ul> <li>Roth Capital shifts to a Hold rating on Callaway Golf (<a href='https://seekingalpha.com/symbol/ELY' title='Callaway Golf Company'>ELY</a> <font color='red'>-4.3%</font>) after having the golf club maker set at Buy. The acquisition of Jack Wolfskin is seen as a potential drag on upcoming earnings reports.</li><li>The firm sets a price target of $17 on ELY.</li> <li>Callaway Golf is now down 31% over the last 90 days.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3417546\" data-linked=\"Roth Capital turns cautious on Callaway Golf\" data-tweet=\"$ELY - Roth Capital turns cautious on Callaway Golf https://seekingalpha.com/news/3417546-roth-capital-turns-cautious-on-callaway-golf?source=tweet\" data-url=\"https://seekingalpha.com/news/3417546-roth-capital-turns-cautious-on-callaway-golf\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417541\" data-ts=\"1545063450\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYL\" target=\"_blank\">MYL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417541-mylan-launches-generic-version-of-shires-lialda-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mylan launches generic version of Shire&#39;s Lialda; shares up 1%</a></h4><ul><li>Mylan N.V. (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color=\"green\">+0.9%</font>) <a href=\"https://seekingalpha.com/pr/17360090-launch-generic-lialda-delayed-release-tablets-expands-mylans-gastroenterology-product\" target=\"_blank\">announces </a>the U.S. launch of its generic version of Shire plc's (<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a> <font color=\"red\">-2.1%</font>) ulcerative colitis med Lialda (mesalamine) Delayed-Release Tablets.</li><li>Per IQVIA, the U.S. market is ~$842M.</li><li>It has also <a href=\"https://seekingalpha.com/pr/17360077-mylan-adds-first-generic-canasa-rectal-suppository-growing-gastroenterology-portfolio\" target=\"_blank\">launched </a>a generic version of Allergan's (<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color=\"green\">+1.5%</font>) Canasa (mesalamine) Rectal Suppository for mildly to moderately active ulcerative proctitis. The U.S. market is ~$263M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417541\" data-linked=\"Mylan launches generic version of Shire&#39;s Lialda; shares up 1%\" data-tweet=\"$MYL $MYL $SHPG - Mylan launches generic version of Shire&#39;s Lialda; shares up 1% https://seekingalpha.com/news/3417541-mylan-launches-generic-version-of-shires-lialda-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3417541-mylan-launches-generic-version-of-shires-lialda-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417540\" data-ts=\"1545063377\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YRCW\" target=\"_blank\">YRCW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417540-yrc-worldwideplus-22-after-playing-defense\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">YRC Worldwide +22% after playing defense</a></h4><ul> <li>YRC Worldwide (NASDAQ:<a href='https://seekingalpha.com/symbol/YRCW' title='YRC Worldwide, Inc.'>YRCW</a>) <font color=\"green\">pops 22%</font> after the company <a href=\"https://seekingalpha.com/pr/17359018-yrc-freight-statement-u-s-government-litigation\" target=\"_blank\">defends</a> itself against the government's complaint on extra shipping charges from its freight subsidiary that dated back to 2013.</li> <li>YRC statement: \"We are confident that the evidence will demonstrate YRC Freight acted consistently with our contract and all applicable guidelines. We look forward to continuing to provide essential and valuable logistics services to the U.S. government and all our customers.\"</li> <li>Analysts are making the case that the government lawsuit doesn't change the fundamental story on the freight shipping stock.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3417540\" data-linked=\"YRC Worldwide +22% after playing defense\" data-tweet=\"$YRCW - YRC Worldwide +22% after playing defense https://seekingalpha.com/news/3417540-yrc-worldwideplus-22-after-playing-defense?source=tweet\" data-url=\"https://seekingalpha.com/news/3417540-yrc-worldwideplus-22-after-playing-defense\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417538\" data-ts=\"1545062894\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OVID\" target=\"_blank\">OVID</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417538-ovids-ov935-shows-positive-action-in-epilepsy-study-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ovid&#39;s OV935 shows positive action in epilepsy study; shares up 1%</a></h4><ul><li>Ovid Therapeutics (<a href='https://seekingalpha.com/symbol/OVID' title='Ovid Therapeutics Inc.'>OVID</a> <font color='green'>+1.3%</font>) <a href=\"https://seekingalpha.com/pr/17359396-ovid-therapeutics-announces-phase-1b-2a-results-ov935-takminus-935-adults-rare-epilepsies\" target=\"_blank\">announces </a>positive results from a Phase 1b/2a evaluating OV935/TAK-925 in 18 adult patients with treatment-resistant rare developmental and epileptic encephalopathies &#40;DEE&#41;.</li><li>The study met the primary endpoint of safety and tolerability and showed a treatment effect in reducing seizure frequency that correlated with decreases in plasma 24-hydroxycholesterol (24HC).</li><li>OV925/TAK-935 inhibits an enzyme called cholesterol 24-hydroxylase (CH24H) which converts cholesterol into 24HC. CH24H plays a key role in the over-activation in a certain metabolic pathway related to CNS disorders like epilepsy.</li><li>Treated patients experienced a 45% reduction in seizure frequency from baseline at day 92. Total seizure-free days at day 92 were 14.0 compared to 11.7 at baseline.</li><li>Enrollment in an open-label extension study, ENDYMION, is in process as are two Phase 2 trials, ELEKTRA and ARCADE.</li><li>The company is developing the candidate with Takeda Pharmaceutical Company (TKPYY <font color='red'>-3.8%</font>) (TAK-935).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3370995-takeda-ovid-therapeutics-expand-clinical-program-takminus-935-ov935\" target=\"_blank\">Takeda and Ovid Therapeutics expand clinical program for TAK-935/OV935</a> (July 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3417538\" data-linked=\"Ovid&#39;s OV935 shows positive action in epilepsy study; shares up 1%\" data-tweet=\"$OVID $OVID $TAK - Ovid&#39;s OV935 shows positive action in epilepsy study; shares up 1% https://seekingalpha.com/news/3417538-ovids-ov935-shows-positive-action-in-epilepsy-study-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3417538-ovids-ov935-shows-positive-action-in-epilepsy-study-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417535\" data-ts=\"1545062690\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DFFN\" target=\"_blank\">DFFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417535-axovant-sciences-among-healthcare-gainers-sophiris-bio-and-molina-healthcare-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axovant Sciences among healthcare gainers; Sophiris Bio and Molina Healthcare among losers</a></h4><ul><li><b>Gainers: </b>Diffusion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a>) <font color=\"green\">+57%</font>. Evofem Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/EVFM' title='Evofem Biosciences, Inc.'>EVFM</a>) <font color=\"green\">+22%</font>. Axovant Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a>) <font color=\"green\">+11%</font>. AgeX Therapeutics (NYSEMKT:<a href='https://seekingalpha.com/symbol/AGE' title='AgeX Therapeutics Inc'>AGE</a>) <font color=\"green\">+14%</font>. Eloxx Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ELOX' title='Eloxx Pharmaceuticals, Inc.'>ELOX</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>Sophiris Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/SPHS' title='Sophiris Bio'>SPHS</a>) <font color=\"red\">-44%</font>. Dova Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DOVA' title='Dova Pharmaceuticals'>DOVA</a>) <font color=\"red\">-27%</font>. LogicBio Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/LOGC' title='LogicBio'>LOGC</a>) <font color=\"red\">-16%</font>.Molina Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/MOH' title='Molina Healthcare, Inc.'>MOH</a>) <font color=\"red\">-14%</font>. Alliqua BioMedical (NASDAQ:<a href='https://seekingalpha.com/symbol/ALQA' title='Alliqua BioMedical, Inc.'>ALQA</a>) <font color=\"red\">-14%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417535\" data-linked=\"Axovant Sciences among healthcare gainers; Sophiris Bio and Molina Healthcare among losers\" data-tweet=\"$DFFN $DFFN $EVFM - Axovant Sciences among healthcare gainers; Sophiris Bio and Molina Healthcare among losers https://seekingalpha.com/news/3417535-axovant-sciences-among-healthcare-gainers-sophiris-bio-and-molina-healthcare-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3417535-axovant-sciences-among-healthcare-gainers-sophiris-bio-and-molina-healthcare-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417525\" data-ts=\"1545061516\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGNX\" target=\"_blank\">RGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417525-chardan-defends-regenxbio-after-bearish-commentary-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chardan defends Regenxbio after bearish commentary; shares up 4%</a></h4><ul><li>REGENXBIO (<a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO'>RGNX</a> <font color=\"green\">+4.3%</font>) is up on below-average volume as Chardan pounds the table defending the stock on the heels of \"bearish comments\" related to its IP portfolio. It says the company's AAV8 patent in Europe recently survived a challenge and global patents protecting AAV9 and AAVrh10 remain valid.</li><li>Shares had sold off over <font color=\"red\">30%</font> in a month before today's action.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3417525\" data-linked=\"Chardan defends Regenxbio after bearish commentary; shares up 4%\" data-tweet=\"$RGNX - Chardan defends Regenxbio after bearish commentary; shares up 4% https://seekingalpha.com/news/3417525-chardan-defends-regenxbio-after-bearish-commentary-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3417525-chardan-defends-regenxbio-after-bearish-commentary-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417521\" data-ts=\"1545061270\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VEDL\" target=\"_blank\">VEDL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417521-vedanta-copper-smelter-ok-to-restart-indian-tribunal-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vedanta copper smelter OK to restart, Indian tribunal says</a></h4><ul><li>Vedanta (<a href='https://seekingalpha.com/symbol/VEDL' title='Vedanta Ltd'>VEDL</a> <font color='green'>+1.9%</font>) is higher after Italy\u2019s National Green Tribunal said the company could <a href=\"https://finance.yahoo.com/news/vedanta-rallies-tribunal-orders-indian-050215131.html\" target=\"_blank\">restart its copper smelter</a>, reversing an order from the Tamil Nadu state government to shut the 400K metric tons/year smelter.</li><li>The tribunal orders the state pollution board to approve the plant\u2019s restart within three weeks and directed VEDL to spend 1B rupees ($14M) on community welfare over three years and implement pollution control and monitoring mechanisms.</li><li>The ruling was in line with the previous recommendations of a panel set up to give its opinion on the smelter.</li><li>In May, the Tamil Nadu government shut the facility after 13 people died when police opened fire on villagers protesting the pollution caused by the plant.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417521\" data-linked=\"Vedanta copper smelter OK to restart, Indian tribunal says\" data-tweet=\"$VEDL - Vedanta copper smelter OK to restart, Indian tribunal says https://seekingalpha.com/news/3417521-vedanta-copper-smelter-ok-to-restart-indian-tribunal-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3417521-vedanta-copper-smelter-ok-to-restart-indian-tribunal-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417517\" data-ts=\"1545060561\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DFFN\" target=\"_blank\">DFFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417517-diffusion-pharma-up-71-on-new-tsc-patent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diffusion Pharma up 71% on new TSC patent</a></h4><ul><li>Thinly traded nano cap Diffusion Pharmaceuticals (<a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color=\"green\">+71%</font>) is up on a 10x surge in volume following its <a href=\"https://seekingalpha.com/pr/17360007-u-s-patent-office-awards-diffusion-exclusive-rights-use-tsc-conjunction-fda-approved-stroke\" target=\"_blank\">announcement </a>that it has been awarded a new U.S. patent covering the use of trans sodium crocetinate &#40;TSC&#41;, in conjunction with tissue plasminogen activator, for the treatment of stroke.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417517\" data-linked=\"Diffusion Pharma up 71% on new TSC patent\" data-tweet=\"$DFFN - Diffusion Pharma up 71% on new TSC patent https://seekingalpha.com/news/3417517-diffusion-pharma-up-71-on-new-tsc-patent?source=tweet\" data-url=\"https://seekingalpha.com/news/3417517-diffusion-pharma-up-71-on-new-tsc-patent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417512\" data-ts=\"1545060113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPHS\" target=\"_blank\">SPHS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417512-sophiris-bio-down-38-on-disappointing-topsalysin-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sophiris Bio down 38% on disappointing topsalysin data</a></h4><ul><li>Thinly traded nano cap Sophiris Bio (<a href='https://seekingalpha.com/symbol/SPHS' title='Sophiris Bio'>SPHS</a> <font color=\"red\">-38.2%</font>) slumps on triple normal volume in response to its <a href=\"https://seekingalpha.com/pr/17359616-sophiris-bio-provides-updates-phase-2b-localized-prostate-cancer-trial\" target=\"_blank\">announcement </a>that prostate cancer patients in a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03081481?lead=sophiris&amp;phase=1&amp;rank=1\" target=\"_blank\">Phase 2b clinical trial</a> who received a second administration of topsalysin experienced no benefit as determined by biopsy.</li><li>27% (n=10/37) of patients responded following a single dose, defined as no detectable tumor on targeted biopsy of the treated lesion or a sufficient reduction to consider the lesion clinically insignificant. Six of the 10 responders experienced complete ablation with no evidence of residual tumors.</li><li>32% (n=12/37) of patients failed to respond to treatment.</li><li>The company is currently seeking a development partner to assist with funding a Phase 3 study.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417512\" data-linked=\"Sophiris Bio down 38% on disappointing topsalysin data\" data-tweet=\"$SPHS - Sophiris Bio down 38% on disappointing topsalysin data https://seekingalpha.com/news/3417512-sophiris-bio-down-38-on-disappointing-topsalysin-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3417512-sophiris-bio-down-38-on-disappointing-topsalysin-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417511\" data-ts=\"1545059844\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSG\" target=\"_blank\">MSG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417511-madison-square-gardenplus-5-on-report-of-potential-knicks-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Madison Square Garden +5% on report of potential Knicks sale</a></h4><ul> <li>Madison Square Garden (<a href='https://seekingalpha.com/symbol/MSG' title='The Madison Square Garden Company'>MSG</a> <font color='green'>+4.9%</font>) pops after New York Knicks owner James Dolan tells ESPN that he isn't ruling out <a href=\"http://www.espn.com/nba/story/_/id/25556830/new-york-knicks-owner-james-dolan-consider-selling-team-bonafide-offer\" target=\"_blank\">selling</a> the NBA team.</li><li>Dolan mentioned $5B as a \"feeler\" number on the Knicks.</li> <li>The Knicks have languished on the court under Dolan's tenure as chairman of MSG, diminishing the star power of the Knicks franchise.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3417511\" data-linked=\"Madison Square Garden +5% on report of potential Knicks sale\" data-tweet=\"$MSG - Madison Square Garden +5% on report of potential Knicks sale https://seekingalpha.com/news/3417511-madison-square-gardenplus-5-on-report-of-potential-knicks-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3417511-madison-square-gardenplus-5-on-report-of-potential-knicks-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417504\" data-ts=\"1545059318\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGIX\" target=\"_blank\">CGIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417504-cancer-genetics-terminates-proposed-merger-novellusdx\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cancer Genetics terminates proposed merger with NovellusDx</a></h4><ul><li>Cancer Genetics (<a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a> <font color='red'>-19.8%</font>) has terminated the <a href=\"https://seekingalpha.com/news/3391204-cancer-genetics-novellusdx-sign-definitive-agreement-merge\" target=\"_blank\">previously-announced merger agreement</a> with NovellusDx, effective immediately.</li><li>The Company will pursue alternative strategic and financial transactions with the goal of enhancing shareholder value.</li><li>John A. Roberts, CEO of Cancer Genetics: \u201cBased on difficulties we have had in advancing the merger process, as well as certain other factors, we believed it was in the best interests of Cancer Genetics and our shareholders to terminate the merger agreement with NovellusDx\".</li></ul><div class=\"tiny-share-widget\" data-id=\"3417504\" data-linked=\"Cancer Genetics terminates proposed merger with NovellusDx\" data-tweet=\"$CGIX - Cancer Genetics terminates proposed merger with NovellusDx https://seekingalpha.com/news/3417504-cancer-genetics-terminates-proposed-merger-novellusdx?source=tweet\" data-url=\"https://seekingalpha.com/news/3417504-cancer-genetics-terminates-proposed-merger-novellusdx\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417499\" data-ts=\"1545058807\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARMK\" target=\"_blank\">ARMK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417499-aramark-services-falls-after-pacific-square-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aramark Services falls after Pacific Square warning</a></h4><ul> <li>Shares of Aramark (<a href='https://seekingalpha.com/symbol/ARMK' title='Aramark Services, Inc.'>ARMK</a> <font color='red'>-4.7%</font>) slump after the retailer is reported to have been <a href=\"https://www.streetinsider.com/Analyst+Comments/Boutique+Out+Negative+on+Aramark+Services+%28ARMK%29/14928765.html\" target=\"_blank\">slapped</a> with an \"orange flag\" rating from Pacific Square.</li> <li>The food service company is seen as have a bloated balance sheet and weak earnings potential.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3417499\" data-linked=\"Aramark Services falls after Pacific Square warning\" data-tweet=\"$ARMK - Aramark Services falls after Pacific Square warning https://seekingalpha.com/news/3417499-aramark-services-falls-after-pacific-square-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3417499-aramark-services-falls-after-pacific-square-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417491\" data-ts=\"1545058112\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRNT\" target=\"_blank\">VRNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417491-verint-acquires-voc-software-provider\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verint acquires VoC software provider</a></h4><ul><li>Verint Systems (<a href='https://seekingalpha.com/symbol/VRNT' title='Verint Systems Inc.'>VRNT</a> <font color='red'>-1.6%</font>) <a href=\"https://seekingalpha.com/filing/4271773\" target=\"_blank\">acquires</a> voice of the customer (VoC) software provider ForeSee for $58.9M in cash plus a deferred payment of $6M.</li><li>As part of the deal, Verint updates its revenue outlook for the fiscal year ending in January 2020 to increases $20M to $1.345B plus or minus 2%. EPS forecast reiterated at $3.50 at the midpoint of the revenue guidance.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417491\" data-linked=\"Verint acquires VoC software provider\" data-tweet=\"$VRNT - Verint acquires VoC software provider https://seekingalpha.com/news/3417491-verint-acquires-voc-software-provider?source=tweet\" data-url=\"https://seekingalpha.com/news/3417491-verint-acquires-voc-software-provider\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417484\" data-ts=\"1545057496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNJN\" target=\"_blank\">FNJN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417484-finjanminus-5-after-jury-sides-juniper\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finjan -5% after jury sides with Juniper</a></h4><ul><li>Finjan (NASDAQ:<a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a>) <font color=\"red\">drops 5.2%</font> after <a href=\"https://seekingalpha.com/pr/17359748-jury-finds-non-infringement-claim-10-finjan-s-494-patent-juniper\" target=\"_blank\">announcing</a> a jury found Juniper Network's (NYSE:<a href='https://seekingalpha.com/symbol/JNPR' title='Juniper Networks'>JNPR</a>) SRX Gateway network doesn't infringe on one claim of Finjan's patent.</li><li>No decision was made regarding the additional claim on that patent, and other patents remain to be tried.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417484\" data-linked=\"Finjan -5% after jury sides with Juniper\" data-tweet=\"$FNJN $FNJN $JNPR - Finjan -5% after jury sides with Juniper https://seekingalpha.com/news/3417484-finjanminus-5-after-jury-sides-juniper?source=tweet\" data-url=\"https://seekingalpha.com/news/3417484-finjanminus-5-after-jury-sides-juniper\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417471\" data-ts=\"1545056704\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CONN\" target=\"_blank\">CONN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417471-oppenheimer-positive-on-conns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oppenheimer positive on Conn&#39;s</a></h4><ul> <li>Oppenheimer walks away from a meeting with Conn's (NASDAQ:<a href='https://seekingalpha.com/symbol/CONN' title='Conn&#39;s, Inc.'>CONN</a>) management with a favorable view on the retailer.</li> <li>Analyst Brian Nagel: \"We do not expect macro-related market worries to lift quickly and are concerned that these fears could continue to weigh upon shares. That said, we are increasingly of the view that investors have turned far too pessemestic on the macro environment and, in the case of CONN, are grossly overlooking substantial underlying improvement in the company\u2019s operating model and now meaningfully enhanced nearer and longer term earnings potential.\"</li> <li>The firm keeps an Outperform rating on Conn's on its expectation that strategic initiatives will take hold.</li><li>Shares of Conn's are down 44% YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3417471\" data-linked=\"Oppenheimer positive on Conn&#39;s\" data-tweet=\"$CONN - Oppenheimer positive on Conn&#39;s https://seekingalpha.com/news/3417471-oppenheimer-positive-on-conns?source=tweet\" data-url=\"https://seekingalpha.com/news/3417471-oppenheimer-positive-on-conns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417467\" data-ts=\"1545056462\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTI\" target=\"_blank\">PTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417467-pti-axon-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PTI, AXON among premarket gainers</a></h4><ul><li>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a>) <font color=\"green\">+18%</font> on <a href=\"https://seekingalpha.com/news/3417444-proteostasis-therapeutics-inks-deal-genentech-shares-19-percent-premarket\" target=\"_blank\">deal</a> with Genentech.</li><li>Axovant Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a>) <font color=\"green\">+12%</font> on <a href=\"https://seekingalpha.com/news/3417424-jefferies-sees-three-bagger-axovant-sciences-premarket-analyst-action\" target=\"_blank\">positive</a> analyst action.</li><li>Evofem Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/EVFM' title='Evofem Biosciences, Inc.'>EVFM</a>) <font color=\"green\">+12%</font> on <a href=\"https://seekingalpha.com/news/3417403-evofem-36-percent-premarket-positive-amphora-results\" target=\"_blank\">positive Amphora results</a>.</li><li>KCAP Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/KCAP' title='KCAP Financial'>KCAP</a>) <font color=\"green\">+10%</font> on <a href=\"https://seekingalpha.com/news/3417406-kcap-convert-externally-managed-bdc-managed-bc-partners\" target=\"_blank\">converting</a> to externally managed BDC managed by BC Partners.</li><li>Ability (NASDAQ:<a href='https://seekingalpha.com/symbol/ABIL' title='Ability Inc.'>ABIL</a>) <font color=\"green\">+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417467\" data-linked=\"PTI, AXON among premarket gainers\" data-tweet=\"$PTI $PTI $AXON-OLD - PTI, AXON among premarket gainers https://seekingalpha.com/news/3417467-pti-axon-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3417467-pti-axon-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417465\" data-ts=\"1545056266\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCLI\" target=\"_blank\">BCLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417465-fda-accepts-brainstorm-s-nurown-ind-application-for-progressive-multiple-sclerosis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Brainstorm\u2019s NurOwn IND application for progressive multiple sclerosis</a></h4><ul><li>The FDA has <a href=\"https://seekingalpha.com/pr/17359540-fda-accepts-brainstorm-s-nurown-ind-application-progressive-multiple-sclerosis\" target=\"_blank\">accepted</a> BrainStorm Cell Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/BCLI' title='BrainStorm Cell Therapeutics Inc.'>BCLI</a>) IND application to initiate a Phase 2 clinical trial of NurOwn for the treatment of progressive multiple sclerosis &#40;MS&#41;.</li>       <li>There are currently no FDA approved autologous cellular therapies addressing MS or other neurological diseases.</li>      <li>Shares are up <font color=\"green\">4%</font> premarket.</li>            </ul><div class=\"tiny-share-widget\" data-id=\"3417465\" data-linked=\"FDA accepts Brainstorm\u2019s NurOwn IND application for progressive multiple sclerosis\" data-tweet=\"$BCLI - FDA accepts Brainstorm\u2019s NurOwn IND application for progressive multiple sclerosis https://seekingalpha.com/news/3417465-fda-accepts-brainstorm-s-nurown-ind-application-for-progressive-multiple-sclerosis?source=tweet\" data-url=\"https://seekingalpha.com/news/3417465-fda-accepts-brainstorm-s-nurown-ind-application-for-progressive-multiple-sclerosis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417463\" data-ts=\"1545055935\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPHS\" target=\"_blank\">SPHS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417463-healthcare-stocks-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare stocks among premarket losers</a></h4><ul><li>Sophiris Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/SPHS' title='Sophiris Bio'>SPHS</a>) <font color=\"red\">-29%</font> after <a href=\"https://seekingalpha.com/pr/17359616-sophiris-bio-provides-updates-phase-2b-localized-prostate-cancer-trial\" target=\"_blank\">providing</a> updates on Phase 2b prostate cancer trial.</li><li>Adial Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADIL' title='ADial Pharmaceuticals, Inc'>ADIL</a>) <font color=\"red\">-10%</font>.</li><li>Alliqua BioMedical (NASDAQ:<a href='https://seekingalpha.com/symbol/ALQA' title='Alliqua BioMedical, Inc.'>ALQA</a>) <font color=\"red\">-8%</font>.</li><li>Finjan Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a>) <font color=\"red\">-8%</font>.</li><li>Tenet Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a>) <font color=\"red\">-8%</font>.</li><li>Centene (NYSE:<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a>) <font color=\"red\">-8%</font>.</li><li>PG&amp;E (NYSE:<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a>) <font color=\"red\">-7%</font>.</li><li>Best Buy (NYSE:<a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a>) <font color=\"red\">-6%</font> on <a href=\"https://seekingalpha.com/news/3417426-best-buy-minus-6-percent-baml-turns-negative\" target=\"_blank\">analyst</a> downgrade.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3417463\" data-linked=\"Healthcare stocks among premarket losers\" data-tweet=\"$SPHS $SPHS $ADIL - Healthcare stocks among premarket losers https://seekingalpha.com/news/3417463-healthcare-stocks-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3417463-healthcare-stocks-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417461\" data-ts=\"1545055840\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCA\" target=\"_blank\">HCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417461-health-insurers-healthcare-providers-in-red-premarket-after-court-ruling-on-obamacare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Health insurers/healthcare providers in the red premarket after court ruling on Obamacare</a></h4><ul><li>Health insurers and care providers are under modest pressure premarket on the heels of a <a href=\"https://seekingalpha.com/news/3417330-federal-judge-strikes-obamacare\" target=\"_blank\">ruling </a>from a Texas court that Obamacare is unconstitutional without the individual mandate. A lengthy appeals process is a certainty.</li><li>Selected tickers: (NYSE:<a href='https://seekingalpha.com/symbol/HCA' title='HCA Holdings, Inc.'>HCA</a>)(<font color=\"red\">-7%</font>); (NYSE:<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a>)(<font color=\"red\">-2%</font>); (NYSE:<a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a>)(<font color=\"red\">-8%</font>); (NYSE:<a href='https://seekingalpha.com/symbol/HUM' title='Humana Inc.'>HUM</a>)(<font color=\"red\">-2%</font>); (NYSE:<a href='https://seekingalpha.com/symbol/CYH' title='Community Health Systems, Inc.'>CYH</a>)(<font color=\"red\">-7%</font>); (NASDAQ:<a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a>)(<font color=\"red\">-1%</font>); (NYSE:<a href='https://seekingalpha.com/symbol/WCG' title='WellCare Health Plans, Inc.'>WCG</a>)(<font color=\"red\">-4%</font>); (NYSE:<a href='https://seekingalpha.com/symbol/MOH' title='Molina Healthcare, Inc.'>MOH</a>)(<font color=\"red\">-6%</font>); (NYSE:<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a>)(<font color=\"red\">-2%</font>); (NYSE:<a href='https://seekingalpha.com/symbol/ANTM' title='Anthem, Inc.'>ANTM</a>)(<font color=\"red\">-3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3417461\" data-linked=\"Health insurers/healthcare providers in the red premarket after court ruling on Obamacare\" data-tweet=\"$HCA $HCA $UNH - Health insurers/healthcare providers in the red premarket after court ruling on Obamacare https://seekingalpha.com/news/3417461-health-insurers-healthcare-providers-in-red-premarket-after-court-ruling-on-obamacare?source=tweet\" data-url=\"https://seekingalpha.com/news/3417461-health-insurers-healthcare-providers-in-red-premarket-after-court-ruling-on-obamacare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417447\" data-ts=\"1545054576\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LZB\" target=\"_blank\">LZB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417447-la-z-boy-rallies-after-sidoti-bump\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">La-Z-Boy rallies after Sidoti bump</a></h4><ul> <li>Shares of La-Z-Boy (NYSE:<a href='https://seekingalpha.com/symbol/LZB' title='La-Z-Boy Incorporated'>LZB</a>) perk up after Sidoti upgrades the retailer to a Buy rating from Neutral.</li> <li>The firm assigns a price target of $34 to rep +30% upside potential.</li> <li>LZB <font color=\"green\">+1.52%</font> premarket to $26.12 vs. a 52-week trading range of $25.57 to $39.15.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3417447\" data-linked=\"La-Z-Boy rallies after Sidoti bump\" data-tweet=\"$LZB - La-Z-Boy rallies after Sidoti bump https://seekingalpha.com/news/3417447-la-z-boy-rallies-after-sidoti-bump?source=tweet\" data-url=\"https://seekingalpha.com/news/3417447-la-z-boy-rallies-after-sidoti-bump\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417445\" data-ts=\"1545054542\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNC\" target=\"_blank\">CNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417445-centene-sees-much-200k-jump-in-peak-enrollment-next-year\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Centene sees as much as 200K jump in peak enrollment next year</a></h4><ul><li>Centene (NYSE:<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a>) expects <a href=\"https://seekingalpha.com/pr/17359729-centene-corporation-announces-updated-2019-marketplace-enrollment-estimate\" target=\"_blank\">peak enrollment</a> in 2019 to exceed this year's by 150K - 200K, significantly above the 50K - 150K outlook presented last week. Both projections exclude ~80K Fidelis marketplace members.</li><li>Shares are down <font color=\"red\">6%</font> premarket, along with many other healthcare stocks.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417445\" data-linked=\"Centene sees as much as 200K jump in peak enrollment next year\" data-tweet=\"$CNC - Centene sees as much as 200K jump in peak enrollment next year https://seekingalpha.com/news/3417445-centene-sees-much-200k-jump-in-peak-enrollment-next-year?source=tweet\" data-url=\"https://seekingalpha.com/news/3417445-centene-sees-much-200k-jump-in-peak-enrollment-next-year\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417444\" data-ts=\"1545054489\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTI\" target=\"_blank\">PTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417444-proteostasis-therapeutics-inks-deal-genentech-shares-up-19-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Proteostasis Therapeutics inks deal with Genentech; shares up 19% premarket</a></h4><ul><li>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a>) <a href=\"https://seekingalpha.com/pr/17359463-proteostasis-therapeutics-announces-global-license-agreement-genentech\" target=\"_blank\">announces</a> a worldwide, exclusive license agreement with Genentech, a member of the Roche Group, for rights to potential therapeutic small molecule modulators of an undisclosed target within the proteostasis network.</li>  <li>Under the terms of the agreement, in exchange for rights to these small molecule modulators, Proteostasis is eligible to receive upfront and milestone payments of over $100M and tiered royalties on sales of medicines resulting from the license agreement.</li><li>Genentech is responsible for all further R&amp;D expenses related to the program. Full financial terms, the therapeutic target and disease areas of focus are not disclosed.</li><li>Shares are up <font color=\"green\">19%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3417444\" data-linked=\"Proteostasis Therapeutics inks deal with Genentech; shares up 19% premarket\" data-tweet=\"$PTI - Proteostasis Therapeutics inks deal with Genentech; shares up 19% premarket https://seekingalpha.com/news/3417444-proteostasis-therapeutics-inks-deal-genentech-shares-up-19-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3417444-proteostasis-therapeutics-inks-deal-genentech-shares-up-19-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417440\" data-ts=\"1545053920\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417440-teva-up-1-premarket-on-positive-fremanezumab-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva up 1% premarket on positive fremanezumab data</a></h4><ul><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) is up <font color=\"green\">1%</font> premarket on modest volume in response to its <a href=\"https://seekingalpha.com/pr/17359599-teva-announces-positive-topline-phase-iiib-results-fremanezumab-adults-migraine-respond\" target=\"_blank\">announcement </a>of positive results from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03308968?titles=focus&amp;lead=teva&amp;rank=1\" target=\"_blank\">FOCUS</a>, evaluating fremanezumab in adults with chronic or episodic migraine.</li><li>Patients receiving the calcitonin gene-related peptide &#40;CGRP&#41; antagonist, either monthly or quarterly, experienced statistically significant reductions in monthly average migraine days compared to placebo (-4.1 days, -3.7 days, -0.6 days, respectively).</li><li>Detailed results will be submitted for presentation at future medical conferences and for publication.</li><li>Migraine-related tickers: (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>)(NASDAQ:<a href='https://seekingalpha.com/symbol/OPTN' title='OptiNose, Inc.'>OPTN</a>)(NYSE:<a href='https://seekingalpha.com/symbol/BHVN' title='Biohaven Pharmaceutical Holding Company Ltd.'>BHVN</a>)(<a href='https://seekingalpha.com/symbol/IGXT' title='IntelGenx Technologies Corp.'>OTCQX:IGXT</a>)(NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>)(NYSE:<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>)(NYSE:<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>)(NASDAQ:<a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a>)(NASDAQ:<a href='https://seekingalpha.com/symbol/ALDR' title='Alder Biopharmaceuticals Inc.'>ALDR</a>)(NASDAQ:<a href='https://seekingalpha.com/symbol/XENE' title='Xenon Pharmaceuticals'>XENE</a>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3417440\" data-linked=\"Teva up 1% premarket on positive fremanezumab data\" data-tweet=\"$TEVA $TEVA $AMGN - Teva up 1% premarket on positive fremanezumab data https://seekingalpha.com/news/3417440-teva-up-1-premarket-on-positive-fremanezumab-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3417440-teva-up-1-premarket-on-positive-fremanezumab-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417439\" data-ts=\"1545053880\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESTC\" target=\"_blank\">ESTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417439-elasticplus-2_7-on-buy-initiation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Elastic +2.7% on Buy initiation</a></h4><ul><li>Monness, Crespi, Hardt &amp; Co initiates Elastic (NYSE:<a href='https://seekingalpha.com/symbol/ESTC' title='Elastic'>ESTC</a>) at Buy with a $100 price target, a 30% upside to Friday's close.</li><li>Source: Bloomberg First Word.</li><li>Elastic's earnings report earlier this month included upside Q3 and FY19 guidance. Q3 has revenue from $64M to $66M and EPS of -$0.32 to -$0.30. Analysts <a href=\"https://seekingalpha.com/symbol/ESTC/earnings/estimates\" target=\"_blank\">expect</a> $65.77M and -$0.30, respectively.</li><li>Elastic shares are <font color=\"green\">up 2.7%</font> premarket to $78.74.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417439\" data-linked=\"Elastic +2.7% on Buy initiation\" data-tweet=\"$ESTC - Elastic +2.7% on Buy initiation https://seekingalpha.com/news/3417439-elasticplus-2_7-on-buy-initiation?source=tweet\" data-url=\"https://seekingalpha.com/news/3417439-elasticplus-2_7-on-buy-initiation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417429\" data-ts=\"1545052963\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRY\" target=\"_blank\">TLRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417429-tilray-secures-supply-of-cannabidiol-isolate-shares-up-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tilray secures supply of cannabidiol isolate; shares up 2% premarket</a></h4><ul><li>Tilray (NASDAQ:<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a>) is up <font color=\"green\">2%</font> premarket on light volume in reaction to its announcement that it has inked a <a href=\"https://seekingalpha.com/pr/17359611-tilray-signs-letter-intent-hemp-derived-cbd-u-s-canada\" target=\"_blank\">binding letter of inten</a>t with LiveWell Canada for hemp-derived cannabidiol &#40;CBD&#41; isolate processed from hemp in the U.S. and Canada. The first shipment should happen in February 2019.</li><li>The company plans to use the CBD isolate to process finished cannabis products for distribution in Canada and the U.S.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417429\" data-linked=\"Tilray secures supply of cannabidiol isolate; shares up 2% premarket\" data-tweet=\"$TLRY - Tilray secures supply of cannabidiol isolate; shares up 2% premarket https://seekingalpha.com/news/3417429-tilray-secures-supply-of-cannabidiol-isolate-shares-up-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3417429-tilray-secures-supply-of-cannabidiol-isolate-shares-up-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417426\" data-ts=\"1545052501\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBY\" target=\"_blank\">BBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417426-best-buyminus-6-after-baml-turns-negative\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Best Buy -6% after BAML turns negative</a></h4><ul> <li>Bank of America Merrill Lynch lowers Best Buy (NYSE:<a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a>) to an Underperform rating from Neutral amid concerns on sales of TVs, gaming products and the Apple business.</li> <li>Overall, the BAML analyst team thinks \"slowing industry growth, tough compares in key products and cost inflation\" hurts the upside case on BBY.</li> <li>\"BBY may see an outright comp miss in 4Q and we believe Street 2019/20 EPS ests are too high,\" warns the firm.</li> <li>The price objective on BBY is dropped all the way to $50 from $70.</li> <li>Shares of Best Buy are <font color=\"red\">down 5.91%</font> premarket to $52.10.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3417426\" data-linked=\"Best Buy -6% after BAML turns negative\" data-tweet=\"$BBY - Best Buy -6% after BAML turns negative https://seekingalpha.com/news/3417426-best-buyminus-6-after-baml-turns-negative?source=tweet\" data-url=\"https://seekingalpha.com/news/3417426-best-buyminus-6-after-baml-turns-negative\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417424\" data-ts=\"1545052422\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLC\" target=\"_blank\">TLC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417424-jefferies-sees-three-bagger-in-axovant-sciences-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies sees three-bagger in Axovant Sciences in premarket analyst action</a></h4><ul><li>Taiwan Liposome (<a href='https://seekingalpha.com/symbol/TLC' title='Taiwan Liposome Co.'>TLC</a>) initiated with Buy rating at Janney Montgomery.</li><li>Argenx (NASDAQ:<a href='https://seekingalpha.com/symbol/ARGX' title='Argenx SE'>ARGX</a>) initiated with Buy rating and $154 (51% upside) price target at Goldman Sachs. Shares up <font color=\"green\">2%</font> premarket.</li><li>Nightstar Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NITE' title='Nightstar Therapeutics plc'>NITE</a>) initiated with Overweight rating and $28 (138% upside) price target at Barclays.</li><li>Axovant Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a>) upgraded to Buy with a $3 (197% upside) price target at Jefferies. Shares up <font color=\"green\">14%</font> premarket.</li><li>Repligen (NASDAQ:<a href='https://seekingalpha.com/symbol/RGEN' title='Repligen Corporation'>RGEN</a>) upgraded to Buy at C.L. King.</li><li>Tenet Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a>) downgraded to Neutral with a $25 (18% upside) price target at Baird. Shares down <font color=\"red\">6% </font>premarket.</li><li>Centene (NYSE:<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a>) removed from Conviction Buy list at Goldman. Shares down <font color=\"red\">8%</font> on court ruling potentially invaliding Obamacare.</li><li>Zealand Pharma A/S (NASDAQ:<a href='https://seekingalpha.com/symbol/ZEAL' title='Zealand Pharma'>ZEAL</a>) downgraded to Neutral at Goldman. Shares down <font color=\"red\">2%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417424\" data-linked=\"Jefferies sees three-bagger in Axovant Sciences in premarket analyst action\" data-tweet=\"$TLC $TLC $ARGX - Jefferies sees three-bagger in Axovant Sciences in premarket analyst action https://seekingalpha.com/news/3417424-jefferies-sees-three-bagger-in-axovant-sciences-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3417424-jefferies-sees-three-bagger-in-axovant-sciences-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417423\" data-ts=\"1545052371\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WFT\" target=\"_blank\">WFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417423-weatherford-to-sell-surface-data-logging-business-for-50m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weatherford to sell surface data logging business for $50M</a></h4><ul><li>Weatherford International (NYSE:<a href='https://seekingalpha.com/symbol/WFT' title='Weatherford International Ltd.'>WFT</a>) <a href=\"https://seekingalpha.com/pr/17359432-weatherford-announces-sale-surface-data-logging-business\" target=\"_blank\">agrees to sell</a> its surface data logging business to Excellence Logging for $50M.</li><li>WFT says it made the sale to help refocus its portfolio on the businesses most closely aligned with its long-term strategy.</li><li>The deal follows WFT's recent sales of its laboratory services business for $205M and international land rigs business for $287.5M.</li><li>WFT <font color=\"red\">-7.9%</font> pre-market.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417423\" data-linked=\"Weatherford to sell surface data logging business for $50M\" data-tweet=\"$WFT $WFTIQ - Weatherford to sell surface data logging business for $50M https://seekingalpha.com/news/3417423-weatherford-to-sell-surface-data-logging-business-for-50m?source=tweet\" data-url=\"https://seekingalpha.com/news/3417423-weatherford-to-sell-surface-data-logging-business-for-50m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417420\" data-ts=\"1545052031\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LULU\" target=\"_blank\">LULU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417420-stifel-sees-attractive-entry-point-on-lululemon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel sees attractive entry point on Lululemon</a></h4><ul> <li>Lululemon (NASDAQ:<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a>) shoots higher in early trading after Stifel Nicolaus <a href=\"https://www.marketwatch.com/story/lululemons-stock-rallies-after-stifel-analyst-says-its-time-to-buy-2018-12-17?\" target=\"_blank\">upgrades</a> the retailer to a Buy rating from Hold.</li> <li>\"While there is no shortage of uncertainty in the market, we view the pullback in shares as an entry point for a high quality large cap growth business with runway,\" advises Stifel analyst Jim Duffy.</li><li>Stifel assigns a price target of $151 to LULU to rep +25% upside potential.</li><li>LULU <font color=\"green\">+1.41%</font> premarket to $120.80. </li></ul><div class=\"tiny-share-widget\" data-id=\"3417420\" data-linked=\"Stifel sees attractive entry point on Lululemon\" data-tweet=\"$LULU - Stifel sees attractive entry point on Lululemon https://seekingalpha.com/news/3417420-stifel-sees-attractive-entry-point-on-lululemon?source=tweet\" data-url=\"https://seekingalpha.com/news/3417420-stifel-sees-attractive-entry-point-on-lululemon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}